[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1004
1. Gundy S, Székely G, Farkas G, Pulay A, Remenár E: [Problems occurring in the application of cytogenetic biomarkers for alcoholics with and without malignant diseases]. Magy Onkol; 2008 Jun;52(2):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify these problems, 432 head and neck cancer patients (HNCP), 62 alcoholics with alcoholic hepatitis (ALCL), and 101 disease-free chronic alcoholics (ALC) were examined.
  • Despite clinically confirmed alcohol-related diagnoses (and GGT and MCV values) only about half of HNCPs and ALCLs reported about any alcohol consumption, in contrast to the realistic self-reports of ALCs.
  • In cytogenetic case control investigations no difference between the spontaneous rate of chromosomal aberrations (CAs) of healthy controls and ALCs was found, however, genetic instability expressed as a 40-50% elevation rate of CAs in HNCPs and ALCLs might be associated with systemic inflammatory reaction of lymphocytes.
  • Bleomycin sensitivity assay showed the highest break/cell (b/c) values not in HNCPs (1.06 b/c) as it was reported earlier, but in "healthy" ALCs (1.52 b/c).

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640891.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM: Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol; 2005 Sep;36(9):939-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
  • In previous studies of anaplastic large cell lymphoma (ALCL), we showed that inhibition of Jak3 down-regulates activated/phosphorylated Stat3 (pStat3), decreases anaplastic lymphoma kinase (ALK) enzymatic activity, and induces cell-cycle arrest and apoptosis in ALK-positive ALCL.
  • These findings implicate Jak3 as playing a significant role in the pathogenesis of ALK-positive ALCL; most likely via Stat3 and ALK activation.
  • To assess this possibility, we used immunohistochemical staining to evaluate the frequency of expression of Jak3 and its activated/phosphorylated form (pJak3) in 48 systemic ALCL tumors included in a tissue microarray. pJak3 was detected in 17 (81%) of 21 ALK-positive tumors, compared with 3 (11%) of 27 ALK-negative tumors (P < .0001, Fisher exact test).
  • pStat3 was present in 12 (86%) of 14 ALK-positive tumors and in 10 (40%) of 25 ALK-negative tumors assessed (P = .0078).
  • Of 12 ALK-positive/pStat3-positive tumors, 8 (67%) expressed pJak3, but none of 10 ALK-negative/pStat3-positive tumors expressed pJak3.
  • We conclude that Jak3 activation is predominantly restricted to ALK-positive ALCL tumors.
  • Most likely, Jak3 collaborates with ALK in activating Stat3, leading to cell survival, cell-cycle progression, and tumor growth.
  • In contrast, the mechanism of Stat3 activation in ALK-negative ALCL tumors appears to be independent of Jak3.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / enzymology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16153455.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / JAK3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


3. Shen M, Huang W, Zhang W, Hao X, Sun WH, Redshaw C: Synthesis and characterisation of alkylaluminium benzimidazolates and their use in the ring-opening polymerisation of ε-caprolactone. Dalton Trans; 2010 Nov 7;39(41):9912-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of L1 with one or two equivalents of Et(2)AlCl led to the adducts EtAl(L1)(2)·AlEtCl(2) (7) or Et(2)AlL1·AlEtCl(2) (8), respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842299.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Sun XW, Sun GL, Xiao LJ: [Evaluation of gingival inflammation related to different retraction agents]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2008 Feb;26(1):53-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quantity of gingival crevicular fluid (GCF) and the active level of aspartate amino-transferase (AST) in gingival crevicular fluid were measured before and 1, 3, 5, 7, 9 days after retracting gingiva by four kinds retraction agents.
  • RESULTS: The change of the GCF from the smallest to the largest was sodium chloride, 0.1% HCl-epinephrine, 25% AlCl,, 15.5% Fe2 (SO)3.
  • CONCLUSION: 0.1% HCl-epinephrine is suggested in patient without cardiovascular disease.
  • For patient with cardiovascular disease, the better substitute is 25% AlCl3.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357884.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 3CYT62D3GA / aluminum chloride; YKH834O4BH / Epinephrine
  •  go-up   go-down


5. Szomor A, Al Saati T, Delsol G, Kereskai L, Szijártó Z, Losonczy H: Primary bone marrow T-cell anaplastic large cell lymphoma with triple M gradient. Pathol Oncol Res; 2007;13(3):260-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone marrow T-cell anaplastic large cell lymphoma with triple M gradient.
  • We present a case of a 60-year-old male patient with primary bone marrow anaplastic large cell lymphoma.
  • Bone marrow biopsy showed massive CD30-positive, ALK-negative large lymphoid cell infiltration of T-cell origin with anaplastic morphology.
  • PCR analysis of lymphoid cells separated from the bone marrow demonstrated the presence of a B/T hybrid genotype disorder with no evidence of the t(2;5), nor t(1;2) translocations.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / immunology. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / immunology. T-Lymphocytes / immunology


6. Skiljevic D, Nikolic MM, Milinkovic M, Bonaci-Nikolic B: Regressing anaplastic CD30-positive large-cell lymphoma of the skin. Acta Dermatovenerol Alp Pannonica Adriat; 2006 Sep;15(3):131-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regressing anaplastic CD30-positive large-cell lymphoma of the skin.
  • Originally believed to be of histiocytic origin, regressing primary cutaneous anaplastic large-cell lymphoma is a CD30 (Ki 1) positive T-cell lymphoma with histologic high grade malignancy, but with an often favorable clinical course with regression of individual lesions.
  • The clinical, histologic, and immunohistochemical findings pointed to CD30 positive primary cutaneous anaplastic large-cell lymphoma.
  • After 2 years of activity, the disease regressed.
  • During the 10-year follow-up period, no signs of disease reactivation were noted.
  • Accurate recognition of this lymphoma is important to avoid unnecessary aggressive treatments.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Leg. Remission, Spontaneous


7. Geissinger E, Sadler P, Roth S, Grieb T, Puppe B, Müller N, Reimer P, Vetter-Kauczok CS, Wenzel J, Bonzheim I, Rüdiger T, Müller-Hermelink HK, Rosenwald A: Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica; 2010 Oct;95(10):1697-704
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
  • BACKGROUND: CD30(+) T-cell lymphoproliferations comprise a spectrum of clinically heterogeneous entities, including systemic anaplastic large cell lymphomas (ALK(-) and ALK(+)) and primary cutaneous CD30(+) T-cell lymphoproliferative disorders.
  • While all these entities are characterized by proliferation of highly atypical, anaplastic CD30(+) T cells, the expression of T-cell specific antigens in the tumor cells is not consistently detectable.
  • DESIGN AND METHODS: We evaluated biopsies from 19 patients with primary cutaneous CD30(+) lymphoproliferative disorders, 38 with ALK(-) and 33 with ALK(+) systemic anaplastic large cell lymphoma.
  • The biopsies were examined for the expression of T-cell receptorαβ/CD3 complex (CD3γ, δ, ε, ζ), transcription factors regulating T-cell receptor expression (ATF1, ATF2, TCF-1, TCF-1α/LEF-1, Ets1), and molecules of T-cell receptor-associated signaling cascades (Lck, ZAP-70, LAT, bcl-10, Carma1, NFATc1, c-Jun, c-Fos, Syk) using immunohistochemistry.
  • RESULTS: In comparison to the pattern in 20 peripheral T-cell lymphomas, not otherwise specified, we detected a highly disturbed expression of the T-cell receptor/CD3 complex, TCF-1, TCF-1α/LEF-1, Lck, ZAP-70, LAT, NFATc1, c-Jun, c-Fos and Syk in most of the systemic anaplastic large cell lymphomas.
  • In addition, primary cutaneous CD30(+) lymphoproliferative disorders showed such a similar expression pattern to that of systemic anaplastic large cell lymphomas, that none of the markers we investigated can reliably distinguish between these CD30(+) T-cell lymphoproliferations.
  • CONCLUSIONS: Severely altered expression of the T-cell receptor/CD3 complex, T-cell receptor-associated transcription factors and signal transduction molecules is a common characteristic of systemic and cutaneous CD30(+) lymphoproliferations, although the clinical behavior of these entities is very different.
  • Since peripheral T-cell lymphomas, not otherwise specified retain the full expression program required for functioning T-cell receptor signaling, the differential expression of a subset of these markers might be of diagnostic utility in distinguishing peripheral T-cell lymphomas, not otherwise specified from the entire group of CD30(+) lymphoproliferations.
  • [MeSH-major] Antigens, CD3 / analysis. Antigens, CD30 / analysis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Receptors, Antigen, T-Cell / analysis


8. Cho-Vega JH, Vega F, Medeiros LJ: An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma. Adv Anat Pathol; 2008 Mar;15(2):105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • (PMID = 18418091.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, Delsol G, Brousset P: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol; 2009 Sep 1;27(25):4211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
  • PURPOSE: Anaplastic lymphoma kinase (ALK) -positive diffuse large B-cell lymphoma (DLBCL) is a rare variant of DLBCL that has been described only in small case reports.
  • PATIENTS AND METHODS: We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or CHOP-like regimens from different institutions to better define the presenting features, clinical course, and response to treatment.
  • All patients expressed ALK fusion proteins, but virtually all were CD30 and CD20 negative.
  • Most patients (60%) followed an aggressive clinical course with advanced stage at diagnosis, frequent marrow infiltration, and poor outcome.
  • Of note, the median survival was only 12.2 months (95% CI, 9.1 to 32.5 months) in patients with advanced-stage disease.
  • CONCLUSION: ALK-positive DLBCLs display clinicopathologic features that distinguish them from common DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / enzymology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Oncogene Proteins, Fusion / analysis. Prednisone / administration & dosage. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2010 Jan 1;28(1):182
  • (PMID = 19636007.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / oncoprotein CLTCL-ALK; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Hubicki Z, Wołowicz A, Leszczyńska M: Studies of removal of palladium(II) ions from chloride solutions on weakly and strongly basic anion exchangers. J Hazard Mater; 2008 Nov 30;159(2-3):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Palladium(II) ions sorption from various chloride solutions of the composition: 0.1-6.0M HCl-0.00056 M Pd(II), 1.0M ZnCl(2)-0.1M HCl-0.00056 M Pd(II), 1.0M AlCl(3)-0.1M HCl-0.00056 M Pd(II) on the weakly and strongly basic anion exchangers (Varion ATM, Varion ADM and Varion ADAM) was discussed.

  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358602.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Chlorides; 0 / Solutions; 5TWQ1V240M / Palladium
  •  go-up   go-down


11. Werner B, Massone C, Kerl H, Cerroni L: Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol; 2008 Dec;35(12):1100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.
  • BACKGROUND: Cutaneous infectious and inflammatory diseases may contain a significant number of CD30-positive cells, thus mimicking lymphomatoid papulosis (LyP) or anaplastic large cell lymphoma.
  • METHODS: We reviewed our cases of non-neoplastic skin conditions with large, CD30-positive cells and searched the literature for similar cases.
  • CD30-positive cells were often arranged in clusters and revealed both Golgi and membrane positivity, similar to what was observed in LyP and CD30+ anaplastic large T-cell lymphoma.
  • CONCLUSIONS: Analysis of our data and of those published in the literature shows that viruses and drugs are the most common cause for occurrence of large CD30-positive cells in cutaneous pseudolymphomatous infiltrates.
  • Arrangement of these large, CD30-positive cells in small clusters is not unique to cutaneous CD30-positive lymphomas, and in many cases a precise diagnosis can be made only upon accurate clinicopathological correlation or using ancillary methods such as polymerase chain reaction analysis for viral DNA.
  • [MeSH-major] Antigens, CD30 / metabolism. Skin Diseases / metabolism. Skin Diseases / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions / metabolism. Drug-Related Side Effects and Adverse Reactions / pathology. Female. Humans. Infant. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Male. Middle Aged. Skin Neoplasms / pathology. Virus Diseases / metabolism. Virus Diseases / pathology


12. Tamiolakis D, Papadopoulos N, Venizelos J, Kakagia D, Nikolaidou S, Bolioti S, Kouskoukis C: ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma. Onkologie; 2005 Jun;28(6-7):356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma.
  • BACKGROUND: Anaplastic lymphoma kinase (ALK) expression has not been described in neutrophil-rich anaplastic large cell lymphoma (NR-ALCL).
  • CASE REPORT: A 12-year old female with a 4-weeks history of a non-resolving bump over the forehead resulting from injury, was diagnosed of stage IE cutaneous T-cell lymphoma, and radiation was employed.
  • Shortly after completion of therapy, there was progress of the disease on the soft tissue of the right hand, and bone marrow involvement was also found.
  • A fine-needle aspiration of the hand mass was performed, and a diagnosis of CD30+/ALK+ NR-ALCL, was rendered.
  • METHODS: We studied the morphological characteristics of CD30+/ALK+ NR-ALCL using histological methods.
  • A panel of antibodies were used to establish diagnosis and subtyping.
  • CONCLUSIONS: ALK-ALCL arising in the skin represents a single disease with a broad spectrum of morphology; clinicians and pathologists should be aware of this neutrophil-rich (NR) variant with aggressive clinical presentation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Neutrophils / pathology. Protein-Tyrosine Kinases / blood. Skin Neoplasms / blood. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933425.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


13. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • BACKGROUND: The burden of lymphomas on the health care system in Nigeria is enormous.
  • Correct diagnosis and identification of aetiological factor are important steps in reducing this burden.
  • Epstein-Barr virus latent membrane protein-1 (LMP-1), CD15 and CD30 immunohistochemistry was also performed.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • 60% of the tumour was EBV positive, all of the MC subtype.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD15 / immunology. Antigens, CD30 / immunology. Biomarkers, Tumor / immunology. Child. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Immunophenotyping. Male. Nigeria. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


14. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, Gao MY, Hua S, Chen C, Kim S, Michellys PY, Lesley SA, Harris JL, Spraggon G: Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J; 2010 Sep 15;430(3):425-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
  • ALK (anaplastic lymphoma kinase) is an RTK (receptor tyrosine kinase) of the IRK (insulin receptor kinase) superfamily, which share an YXXXYY autophosphorylation motif within their A-loops (activation loops).
  • Chromosomal translocations involving ALK were first identified in anaplastic large-cell lymphoma, a subtype of non-Hodgkin's lymphoma, where aberrant fusion of the ALK kinase domain with the NPM (nucleophosmin) dimerization domain results in autophosphosphorylation and ligand-independent activation.
  • The A-loop adopts an inhibitory pose where a short proximal A-loop helix (alphaAL) packs against the alphaC helix and a novel N-terminal beta-turn motif, whereas the distal portion obstructs part of the predicted peptide-binding region.
  • [MeSH-minor] Adenosine Diphosphate / chemistry. Adenosine Diphosphate / metabolism. Amino Acid Motifs / genetics. Amino Acid Sequence. Animals. Cell Line. Crystallization. Crystallography, X-Ray. Humans. Kinetics. Models, Molecular. Molecular Sequence Data. Mutagenesis. Neuroblastoma / enzymology. Neuroblastoma / genetics. Phosphorylation. Protein Binding. Receptor Protein-Tyrosine Kinases. Sequence Homology, Amino Acid. Spodoptera. Staurosporine / chemistry. Staurosporine / metabolism. Substrate Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20632993.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mutant Proteins; 61D2G4IYVH / Adenosine Diphosphate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; H88EPA0A3N / Staurosporine
  •  go-up   go-down


15. Savage KJ: Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2008;:280-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and primary therapy in peripheral T-cell lymphomas.
  • Peripheral NK/T-cell neoplasms are an uncommon group of diseases that show distinct racial and geographic variation.
  • The prognostic significance of the T-cell phenotype has been clearly defined in recent studies by using modern lymphoma classification systems.
  • However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic gammadelta T-cell lymphomas).
  • Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.
  • Given disease rarity and biological heterogeneity, advances in diagnosis, prognosis and treatment have lagged behind DLBCL.
  • Recently, however, studies are emerging that focus specifically on PTCLs with the ultimate goal of better understanding disease biology and developing more effective therapies.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074097.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone
  •  go-up   go-down


16. Sridharan M, Prasad KJ, Ngendahimana A, Zeller M: 2,2-Dimethyl-2,3-dihydro-pyrano[2,3-a]carbazol-4(11H)-one. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 11):o2155
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The title compound, C(17)H(15)NO(2), was prepared from 1-hydroxy-carbazole and 3,3-dimethyl-acrylic acid with a mixture of AlCl(3) and POCl(3) as the cyclization catalyst.
  • In the crystal structre, strong N-H⋯O hydrogen bonds and weaker C-H⋯π inter-actions occur, and a slipped π-π stacking inter-action [centroid-centroid separation = 3.8425 (8) Å] is also observed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Rev. 2002 Nov;102(11):4303-427 [12428991.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 11):o2157 [21581017.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 11):o2156 [21581016.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21581015.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2959512
  •  go-up   go-down


17. Cheng M, Ott GR: Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anticancer Agents Med Chem; 2010 Mar;10(3):236-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
  • Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was originally identified as the oncogenic NPM (nucleophosmin)-ALK fusion protein due to a t (2;5) chromosomal translocation in anaplastic large cell lymphomas.
  • The recent reports of EML4 (echinoderm microtubule-associated protein-like 4)-ALK oncogenic proteins in non-small cell lung cancer (NSCLC) and the identification of ALK activating point mutations and gene amplification in neuroblastoma have indicated ALK as a potential major therapeutic target for human cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neuroblastoma / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors


18. Gualco G, Klumb CE, Barber GN, Weiss LM, Bacchi CE: Pediatric lymphomas in Brazil. Clinics (Sao Paulo); 2010;65(12):1267-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric lymphomas in Brazil.
  • OBJECTIVE: This study provides the clinical pathological characteristics of 1301 cases of pediatric/adolescent lymphomas in patients from different geographic regions of Brazil.
  • METHODS: A retrospective analyses of diagnosed pediatric lymphoma cases in a 10-year period was performed.
  • We believe that it represents the largest series of pediatric lymphomas presented from Brazil.
  • RESULTS: Non-Hodgkin lymphomas represented 68% of the cases, including those of precursor (36%) and mature (64%) cell origin.
  • Mature cell lymphomas comprised 81% of the B-cell phenotype and 19% of the T-cell phenotype.
  • Hodgkin lymphomas represented 32% of all cases, including 87% of the classical type and 13% of nodular lymphocyte predominant type.
  • Among mature B-cell lymphomas, most of the cases were Burkitt lymphomas (65%), followed by diffuse large B-cell lymphomas (24%).
  • In the mature T-cell group, anaplastic large cell lymphoma, ALK-positive was the most prevalent (57%), followed by peripheral T-cell lymphoma, then not otherwise specified (25%).
  • In the group of classic Hodgkin lymphomas, the main histological subtype was nodular sclerosis (76%).
  • [MeSH-major] Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):28-33 [19864230.001]
  • [Cites] Semin Oncol. 2009 Oct;36(5):381-418 [19835736.001]
  • [Cites] Cancer Epidemiol. 2009 Dec;33(6):403-5 [19833572.001]
  • [Cites] Int J Cancer. 2010 Feb 1;126(3):715-20 [19642142.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 May;24(4):269-73 [11972094.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):25-30 [12109852.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:147-52 [12401681.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1782-9 [12721255.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):57-66 [12802810.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2622-31 [14642924.001]
  • [Cites] Clin Lymphoma. 2003 Dec;4(3):161-8 [14715098.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1687-9 [15370226.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):407-13 [15455481.001]
  • [Cites] Cancer. 2000 May 15;88(10):2378-86 [10820362.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] Cad Saude Publica. 2002 Jan-Feb;18(1):33-44 [11910422.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Cancer. 1978 Aug;42(2):787-92 [687386.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):77-83 [7505777.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1993 Oct;17(3):337-8 [8271140.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):90-4 [8531859.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):243-8 [8972760.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):92-8 [8980374.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):248-54 [9078320.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):519-25 [9324338.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):465-9 [15621841.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):109-15 [15894921.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Sao Paulo Med J. 2005 May 2;123(3):134-6 [16021277.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):616-22 [16127683.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):210-4 [16123999.001]
  • [Cites] Curr Oncol Rep. 2006 Sep;8(5):387-94 [16901400.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):568-74 [17006262.001]
  • [Cites] Hum Hered. 2006;62(4):190-5 [17106202.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):139-44 [16642484.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):179-85 [17526010.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):761-8 [17760808.001]
  • [Cites] Curr Oncol Rep. 2007 Nov;9(6):459-65 [17991353.001]
  • [Cites] J Pediatr (Rio J). 2007 Nov-Dec;83(6):547-54 [18074060.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Apr;30(4):285-91 [18391697.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):196-201 [18227720.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):910-6 [18464110.001]
  • [Cites] Pediatrics. 2008 Jun;121(6):e1470-7 [18519450.001]
  • [Cites] Hematology. 2008 Apr;13(2):114-8 [18616879.001]
  • [Cites] Pediatr Blood Cancer. 2008 Sep;51(3):369-74 [18493992.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Am J Clin Pathol. 2008 Dec;130(6):946-56 [19019773.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Am J Surg Pathol. 2009 Dec;33(12):1815-22 [19816150.001]
  • (PMID = 21340214.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI073961
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC3020336
  •  go-up   go-down


19. d'Amore ES, Menin A, Bonoldi E, Bevilacqua P, Cazzavillan S, Donofrio V, Gambini C, Forni M, Gentile A, Magro G, Boldrini R, Pillon M, Rosolen A, Alaggio R: Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol; 2007 May-Jun;10(3):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphomas: a study of 75 pediatric patients.
  • In this article, we describe the morphologic and immunophenotypic features of 75 cases of pediatric anaplastic large cell lymphoma (ALCL).
  • According to the World Health Organization classification, 49 cases were common subtype ALCL, and respectively, 3, 6, and 17 cases were small cell, lymphohistiocytic, or mixed histologic variants.
  • Anaplastic lymphoma kinase positivity was detected in 90.7% of the tumors and, using a panel of 9 T-cell surface markers, 88% could be assigned to the T-cell lineage.
  • A molecular analysis for the T-cell receptor gamma (TCR- gamma) and the heavy chain of the immunoglobulin H rearrangements was performed on 6/9 ALCLs with a null immunophenotype, and a TCR clonal pattern was detected in 5/6 cases.
  • Clusterin, CD83, and Pax5, respectively, expressed in 91.3%, 1.7%, and 0% of the ALCLs, were useful biomarkers for the differential diagnosis with Hodgkin's lymphomas.
  • [MeSH-major] Antigens, CD / immunology. Antigens, CD56 / immunology. B-Cell-Specific Activator Protein / immunology. Biomarkers, Tumor / immunology. Clusterin / immunology. Immunoglobulins / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. Membrane Glycoproteins / immunology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Granzymes / immunology. Hodgkin Disease / diagnosis. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. Immunophenotyping. Lymphocytes, Null / immunology. Lymphocytes, Null / pathology. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Perforin. Poly(A)-Binding Proteins / immunology. Pore Forming Cytotoxic Proteins / immunology. Receptors, Antigen, T-Cell, gamma-delta / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Dev Pathol. 2007 May-Jun;10(3):169-71 [17535094.001]
  • (PMID = 17535098.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / CD83 antigen; 0 / CLU protein, human; 0 / Clusterin; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / PAX5 protein, human; 0 / Poly(A)-Binding Proteins; 0 / Pore Forming Cytotoxic Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TIA1 protein, human; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  •  go-up   go-down


20. Wang XQ, Sino-US Leukemia Cooperative Group of Shanghai: [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
  • OBJECTIVE: To investigate the relationship between histopathological subtype of non-Hodgkin' s lymphoma(NHL) and chromosomal abnormalities, and compare the difference of chromosomal abnormalities between China and the West.
  • RESULTS: Diffuse large B-cell lymphoma( DLBCL) constituted 38.1% of the cases followed by follicular lymphoma(FL) 17.4% , small lymphocytic lymphoma( SLL) 10.3% , peripheral T-cell lymphoma ( PTCL) ( unspecified) 8.4%, and angioimmunoblastic lymphoma 7.1%.
  • The incidence of chromosomal abnormalities among FL, SLL, DLBCL, anaplastic large cell lymphoma (ALCL) and precursor T-cell lymphoblastic lymphoma (TLBL) was 96.3% , 87.5% , 86.4%, 83.3% and 83.3%, respectively.
  • The most frequent structural abnormalities in DLBCL involved chromosomes 3, 6, 14 and 1, with had high frequencies of 3q27 (41.2%) and 6q21, 6q23, 6q25 involvement (23.5%).
  • The positive rate of IgH rearrangement was 40.
  • Normal karyotype was observed in 8/11 cases with angioimmunoblastic T-cell lymphoma patients.
  • The incidence of chromosomal abnormalities in angioimmunoblastic T-cell lymphoma was lower than that in the West.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Chromosome Structures. Cytogenetic Analysis. Female. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343195.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Zayour M, Gilmore E, Heald P, Rose M, Poligone B, Lazova R: A distinct entity in the spectrum of the CD30+ cutaneous lymphoproliferative diseases: oligolesional nodules with pseudoepitheliomatous hyperplasia followed by spontaneous resolution. Am J Dermatopathol; 2009 Feb;31(1):37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A distinct entity in the spectrum of the CD30+ cutaneous lymphoproliferative diseases: oligolesional nodules with pseudoepitheliomatous hyperplasia followed by spontaneous resolution.
  • Pseudoepitheliomatous hyperplasia (PEH) in biopsies of CD30+ anaplastic large-cell lymphoma (ALCL) is present infrequently and is of unknown prognostic value and significance.
  • Our goal was to review the clinicopathologic features of cases of ALCL with PEH, study their course, and review the literature on the subject.
  • Biopsy specimens of all cases of CD30+ lymphoproliferative disorders (59) were retrieved from the files of Yale Dermatopathology Laboratory over a 17-year period and reviewed.
  • We identified 4 cases of ALCL (7%) exhibiting prominent PEH.
  • In 2 patients, the lesions spontaneously regressed within a few months after initial diagnosis.
  • One patient chose to have an excision in which only a small number of CD30+ cells were present.
  • In the spectrum of CD30+ lymphoproliferative disorders, cases of ALCL with PEH are infrequent.
  • In addition to the 4 cases described here, in our review of the literature we found 35 cases of ALCL with PEH.
  • In the majority of these cases, the lesions started showing evidence of clinical spontaneous regression and even complete resolution within a few months of initial diagnosis.
  • The clinicopathologic correlation between ALCL and PEH has not been emphasized.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Diseases / complications. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155723.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


22. Choi IH, Kim JN, Kwon YM: Effects of chemical treatments on pH and bacterial population in poultry litter: a laboratory experiment. Br Poult Sci; 2008 Sep;49(5):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2. Litter obtained from poultry houses was treated with three chemical treatments (alum, AlCl(3) and FeSO(4)) at the same concentration (8 g/100 g litter), while untreated litter served as a control.
  • However, a significant difference in gram-negative bacteria did not exist among chemical treatments at 0, 1 and 2 weeks.
  • 4. These results suggest that the reduction in total aerobic bacteria and gram-negative bacteria populations is highly related to a decrease in litter pH, and acidifying treatment (alum, AlCl(3) and FeSO(4)) of poultry litter may serve as a means to help the reduction in pathogen populations and to improve economical benefits under commercial production conditions.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM SULFATE .
  • Hazardous Substances Data Bank. ALUM, POTASSIUM .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. FERROUS SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836894.001).
  • [ISSN] 1466-1799
  • [Journal-full-title] British poultry science
  • [ISO-abbreviation] Br. Poult. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alum Compounds; 0 / Aluminum Compounds; 0 / Chlorides; 0 / Ferrous Compounds; 10043-01-3 / aluminum sulfate; 39R4TAN1VT / ferrous sulfate; 3CYT62D3GA / aluminum chloride
  •  go-up   go-down


23. Carmichael MG: Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy. Mil Med; 2007 Jun;172(6):673-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
  • Anaplastic large cell lymphoma (ALCL) is 1 of 17 mature T cell neoplasms described by the World Health Organization.
  • Primary central nervous system (PCNS) ALCL represents a distinct rare form of this family of non-Hodgkin lymphoma and discussions of prognosis and management are limited to case reports and case series.
  • Therapies for this disease largely parallel that of other PCNS lymphomas.
  • We report the case of a 38-year-old male soldier who presented with a parieto-occipital mass lesion and neurological sequelae without evidence of systemic disease.
  • Pathologic evaluation of tissue from brain biopsy confirmed ALCL.
  • We elected treatment with an intensive combination of systemic and intrathecal chemotherapy with radiotherapy.
  • Tailored therapies for PCNS ALCL are unavailable and this regimen may be an option for patients who can tolerate intensive treatments.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615857.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Zidane F, Drogui P, Lekhlif B, Bensaid J, Blais JF, Belcadi S, El Kacemi K: Decolourization of dye-containing effluent using mineral coagulants produced by electrocoagulation. J Hazard Mater; 2008 Jun 30;155(1-2):153-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The best performances of dye removal were obtained with C(2) having a chemical structure comprised of a mixture of polymeric specie (Al45O45(OH)45Cl) and monomeric species (AlCl(OH)2.2H2O and Al(OH)3).

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM HYDROXIDE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155356.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Coloring Agents; 0 / Minerals; 0 / Triazines; 0 / Water Pollutants, Chemical; 451W47IQ8X / Sodium Chloride; 55X04QC32I / Sodium Hydroxide; 61931-52-0 / Procion Red HE-7B
  •  go-up   go-down


25. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM: A novel method of 18F radiolabeling for PET. J Nucl Med; 2009 Jun;50(6):991-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A solution of AlCl(3).6H(2)O in a pH 4.0 sodium-acetate buffer was mixed with an aqueous solution of (18)F to form the Al(18)F complex.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443594.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / 1 R43 EB003751-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes
  •  go-up   go-down


26. Pan GB, Freyland W: In situ STM investigation of spinodal decomposition and surface alloying during underpotential deposition of Cd on Au(111) from an ionic liquid. Phys Chem Chem Phys; 2007 Jul 7;9(25):3286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ STM investigation of spinodal decomposition and surface alloying during underpotential deposition of Cd on Au(111) from an ionic liquid.
  • The electrodeposition and anodic dissolution of Cd on Au(111) in an acidic chloroaluminate ionic liquid (MBIC-AlCl(3), 42 : 58 mol%) have been investigated by cyclic voltammetry and in situ STM.
  • In the Cd underpotential deposition region, various nanostructures can be distinguished.
  • At a potential of 0.95 V vs. Al/Al(iii), a transformation from a well ordered AlCl(4)(-) adlayer to a ( radical3 x radical19) superstructure, presumably due to Cd-AlCl(4)(-) coadsorption, is observed.
  • Reducing the potential to 0.45 V, surface alloying of Cd and Au occurs, which is evidenced for the first time by typical spinodal structures occurring both during deposition and dissolution of the surface alloy layer having a hexagonal structure.
  • At still lower potentials below 0.21 V, a layer-by-layer growth of bulk Cd sets in.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579737.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 0 / Aluminum Compounds; 0 / Cations; 0 / Chlorides; 0 / Ionic Liquids; 00BH33GNGH / Cadmium; 3CYT62D3GA / aluminum chloride; 7440-57-5 / Gold
  •  go-up   go-down


27. Chao-Lo MP, King-Ismael D, Lopez RA: Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep; 2008 Oct 11;2(3):31-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.
  • Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of non-Hodgkin's lymphoma comprising approximately 0.9-9.0% of all cutaneous lymphomas.
  • PCALCL is characterized by the absence of systemic involvement, spontaneous regression and low recurrence rate especially in localized lesions.We present a 47-year-old female with a 1½-year history of two asymptomatic erythematous indurated plaques on the right arm.
  • Skin punch biopsy revealed dense infiltrates of non-epidermotropic, large, irregularly-shaped lymphocytes with hyperchromatic and pyknotic nuclei.
  • Immunohistochemistry revealed that these atypical cells are anaplastic lymphoma kinase (ALK) positive, CD30+, CD3-, CD20- and epithelial membrane antigen (EMA) negative.
  • Work-ups revealed no systemic involvement.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):857-61 [10321635.001]
  • [Cites] Eur J Pediatr. 2008 Jan;167(1):111-3 [17219127.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):793-6 [11050582.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):142-7 [12652196.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1049-58 [14639383.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):168-71 [17642599.001]
  • [Cites] Blood. 2007 Jul 15;110(2):479-84 [17339420.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1319-32, vii-viii [14710887.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1):103-10 [15243534.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):221-6 [16104878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:323-30, 513 [17124079.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):422-8 [11048978.001]
  • (PMID = 21886709.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157779
  • [Keywords] NOTNLM ; lymphomatoid papulosis / lymphoproliferative disorders / mycosis fungoides / primary cutaneous CD30 positive large T cell lymphoma / primary cutaneous anaplastic large cell lymphoma
  •  go-up   go-down


28. Wang QQ, Wang DX, Yang HB, Huang ZT, Wang MX: Synthesis, structure and molecular recognition of functionalised tetraoxacalix[2]arene[2]triazines. Chemistry; 2010 Jun 25;16(24):7265-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AlCl(3)-mediated deallylation and debenzylation reactions afforded the lower-rim dihydroxy-substituted tetraoxacalix[2]arene[2]triazine derivatives 11 and 13 in good yields.
  • The dihydroxylated tetraoxacalix[2]arene[2]triazine 13 b, which gives a mixture of monomer and dimer in solution according to a diffusion NMR spectroscopy study, adopts a 1,3-alternate conformation and forms a cyclic tetrameric assembly in the solid state due to the formation of intermolecular hydrogen-bonding networks.
  • This dihydroxylated macrocyclic host molecule, a hydrogen-bond donor macrocycle with a V-shaped cleft, interacts with 2,2'-bipyridine, 4,4'-bipyridine and 1,10-phenanthroline guests.
  • Hydrogen-bonding interactions, along with other non-covalent interactions, such as lone-pair-electron-pi and C-H...pi interactions, were found to be the driving force for the formation of host-guest complexes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20468032.001).
  • [ISSN] 1521-3765
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Macrocyclic Compounds; 0 / Triazines; 0 / tetraoxacalix(2)arene(2)triazine; 130036-26-9 / Calixarenes
  •  go-up   go-down


29. Kim IS, Shin SY, Kim YS, Kim HY, Yoon HS: Expression of a glutathione reductase from Brassica rapa subsp. pekinensis enhanced cellular redox homeostasis by modulating antioxidant proteins in Escherichia coli. Mol Cells; 2009 Nov 30;28(5):479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The BrGR-expressing E. coli cells showed increased GR activity and tolerance to H(2)O(2), menadione, and heavy metal (CdCl(2), ZnCl(2) and AlCl(2))-mediated growth inhibition.
  • A proteomic analysis demonstrated the higher level of induction of proteins involved in glycolysis, detoxification/oxidative stress response, protein folding, transport/binding proteins, cell envelope/porins, and protein translation and modification when exposed to H(2)O(2) stress.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. MENADIONE .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936628.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Proteome; 0 / Recombinant Proteins; 00BH33GNGH / Cadmium; 723JX6CXY5 / Vitamin K 3; BBX060AN9V / Hydrogen Peroxide; EC 1.8.1.7 / Glutathione Reductase; J41CSQ7QDS / Zinc
  •  go-up   go-down


30. Liu A, Sugisaki Y, Hosone M, Namimatsu S, Maeda S, Naito Z, Ghazizadeh M: CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma. J Clin Pathol; 2009 Sep;62(9):840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive diffuse large B-cell lymphoma with microvillous features: so-called microvillous lymphoma.
  • A case of CD30-positive microvillous lymphoma (MVL) in an 87-year-old man who was encountered generalised lymphadenopathy is presented.
  • Histopathologically, the tumour showed a morphological mimic of anaplastic large cell lymphoma (ALCL) with sinusoidal growth pattern.
  • Immunohistochemically (IHC), the tumour cells were CD30(+), CD20(+), CD45(+), BCL-2(+), BCL-6(+), MUM1(+), Ki-67(+), CD45RO(-), CD3(-), CD10(-), CD15(-), CD56(-), EMA(-), TIA-1(-) and ALK(-).
  • Electron microscopically, the tumour cells were similar to large transformed lymphocytes and had circumferentially profuse microvillous projections resembling those of epithelial mesothelioma cells.
  • In conclusion, CD30-positive MVLs are indistinguishable from ALCLs that have ultrastructural microvillous projections by morphology alone.
  • However, the lack of EMA, TIA-1 and ALK expression in this MVL case facilitated a definite distinction from ALCLs.
  • The results of a panel of three markers (CD10(-), Bcl-6(+) and MUM1(+)) suggested that the present case of CD30-positive MVLs has an activated non-germinal centre B-cell origin.
  • [MeSH-major] Antigens, CD30 / analysis. Lymphoma, Large B-Cell, Diffuse / ultrastructure
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Male. Microscopy, Electron. Microvilli / ultrastructure

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126565.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Cağlar K, Akyüz C, Uner A, Kutluk T, Yalçin B, Varan A, Büyükpamukçu M: Anaplastic large cell lymphoma in a child presenting with cutaneous nodules and blisters. Turk J Pediatr; 2005 Apr-Jun;47(2):188-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a child presenting with cutaneous nodules and blisters.
  • In another hospital, histopathological diagnosis of a skin biopsy was reported to be consistent with tuberculosis and she was treated with antimycobacterial drugs.
  • At our center, histopathological diagnosis was anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL).
  • Eight months after initial admisision, she experienced cutaneous recurrence of disease while on maintenance protocol.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052864.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


32. Salama S: Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol; 2005 Jun;27(3):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review.
  • Posttransplantation lymphoproliferative disorders (PTLD) presenting clinically in the skin are rare and usually of B-cell phenotype.
  • Only 7 cases of cutaneous T-cell PTLD have been previously reported, mostly mycosis fungoides type, with no known cases of "cutaneous" presentation by CD30 (Ki-1) anaplastic large cell lymphoma (ALCL).
  • Initial biopsy showed ALCL involving the dermis with a background rich in neutrophils.
  • The neoplastic cells were of T-cell phenotype, strongly CD30 with typical staining, and BCL-2 positive, but P53 negative.
  • Twenty-two months following diagnosis, he died of cardiac failure with terminal myocardial infarct.
  • There was however no clinical evidence of systemic spread of the lymphoma.This report adds to the clinical and morphologic spectrum of these rare "cutaneous" lymphomas of T-cell lineage arising in the posttransplantation setting, and suggests that EBV does not play a role in their pathogenesis.
  • [MeSH-major] Immunocompromised Host. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Neutrophils / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Antigens, CD30 / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Panniculitis / etiology. Panniculitis / metabolism. Panniculitis / pathology. Polymerase Chain Reaction. Subcutaneous Tissue / pathology


33. Borchmann P: CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis. Cancer Treat Res; 2008;142:349-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic. Lymphomatoid Papulosis. Skin Neoplasms


34. Pena LB, Zawoznik MS, Tomaro ML, Gallego SM: Heavy metals effects on proteolytic system in sunflower leaves. Chemosphere; 2008 Jun;72(5):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was recently demonstrated that under severe Cd stress sunflower (Helianthus annuus L.) proteasome activity is reduced and this results in accumulation of oxidized proteins.
  • Ten days old sunflower plants were transferred to hydroponic culture solutions devoid (control) or containing 100 microM of AlCl(3), CoCl(2), CuCl(2), CrCl(3), HgCl(2), NiCl(2), PbCl(2) or ZnCl(2) and analyzed for protein oxidative damage and proteolytic activities.

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462779.001).
  • [ISSN] 0045-6535
  • [Journal-full-title] Chemosphere
  • [ISO-abbreviation] Chemosphere
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metals, Heavy; 0 / Plant Proteins; 0 / Ubiquitin; 059QF0KO0R / Water; EC 3.4.- / Peptide Hydrolases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


35. Opiso E, Sato T, Yoneda T: Adsorption and co-precipitation behavior of arsenate, chromate, selenate and boric acid with synthetic allophane-like materials. J Hazard Mater; 2009 Oct 15;170(1):79-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solutions containing 100 or 150 mmol of AlCl(3)x6H(2)O were mixed to 100 mmol of Na(4)SiO(4) and the pH were adjusted to 6.4+/-0.3.

  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM SELENATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493614.001).
  • [ISSN] 1873-3336
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Boric Acids; 0 / Chromates; 0 / Environmental Pollutants; 0 / Selenium Compounds; HV0Y51NC4J / Selenic Acid; R57ZHV85D4 / boric acid
  •  go-up   go-down


36. Mourali J, Bénard A, Lourenço FC, Monnet C, Greenland C, Moog-Lutz C, Racaud-Sultan C, Gonzalez-Dunia D, Vigny M, Mehlen P, Delsol G, Allouche M: Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol; 2006 Aug;26(16):6209-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
  • Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, initially discovered as part of the NPM-ALK fusion protein, resulting from the t(2;5) translocation that is frequently associated with anaplastic large-cell lymphomas.
  • In contrast, we now show that Jurkat cells overexpressing the wild-type ALK receptor are more sensitive to doxorubicin-induced apoptosis than parental cells.
  • In order to assess the role of ALK in neural cell-derived tissue, we transiently expressed ALK in the 13.S.1.24 rat neuroblast immortalized cell line.
  • ALK expression led to apoptotic cell death of the neuroblasts.
  • ALK ligation by specific activating antibodies decreased ALK-facilitated apoptosis in both lymphoid and neuronal cell lines.
  • [MeSH-major] Apoptosis. Caspases / metabolism. Protein-Tyrosine Kinases / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Animals. Antibodies / immunology. Aspartic Acid / genetics. Caspase 3. Cell Line, Tumor. Cell Membrane / metabolism. Cerebral Cortex / cytology. Cerebral Cortex / enzymology. Doxorubicin / pharmacology. Enzyme Activation. Gene Expression. Humans. Jurkat Cells. Mice. Mutation / genetics. Neurons / cytology. Neurons / enzymology. Protein Processing, Post-Translational. Rats. Rats, Sprague-Dawley. Receptor Protein-Tyrosine Kinases. Transfection

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21 [11248093.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2715-22 [11387206.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6517-23 [11522649.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] J Cell Biol. 2001 Oct 29;155(3):459-70 [11684710.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7386-97 [11704868.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):466-74 [11751994.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4540-6 [12036886.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Biol Cell. 2003 Oct;95(7):425-36 [14597260.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1464-71 [14563642.001]
  • [Cites] Physiol Rev. 2004 Apr;84(2):411-30 [15044679.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3319-29 [15226403.001]
  • [Cites] Sci STKE. 2004 Jun 29;2004(239):re9 [15226512.001]
  • [Cites] Blood. 1989 Jun;73(8):2155-64 [2525056.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1415-20 [8068938.001]
  • [Cites] Development. 1995 Jan;121(1):37-51 [7867507.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1789-99 [8895526.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] J Neurochem. 1997 Nov;69(5):1870-81 [9349530.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1317-22 [9721090.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):875-86 [9736036.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] Curr Opin Hematol. 1999 Jan;6(1):44-50 [9915553.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10328-39 [15542841.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26039-48 [15886198.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):357-66 [16041752.001]
  • [Cites] J Comp Neurol. 2006 Mar 10;495(2):202-12 [16435287.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1879-90 [10601362.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4056-63 [10921886.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • (PMID = 16880530.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Receptors, Cell Surface; 30KYC7MIAI / Aspartic Acid; 80168379AG / Doxorubicin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1592804
  •  go-up   go-down


37. Khor TS, Alessandri AJ, Jevon GP: Infant anaplastic large cell lymphoma with hemophagocytic syndrome. Pediatr Dev Pathol; 2010 Jan-Feb;13(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant anaplastic large cell lymphoma with hemophagocytic syndrome.
  • Anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive, is uncommon in infancy.
  • We present an unusual occurrence of infant ALCL, ALK-positive, associated with hemophagocytic syndrome.
  • To the best of our knowledge, there have been no cases of infant ALCL, ALK-positive, described that have been associated with hemophagocytic syndrome.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Chromosomes, Human, Pair 2. Failure to Thrive. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Lymph Nodes / pathology. Male. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863446.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


38. Economopoulos T, Papageorgiou S, Dimopoulos MA, Pavlidis N, Tsatalas C, Symeonidis A, Foudoulakis A, Pectasides D, Rontogianni D, Rizos E, Chalkia P, Anagnostopoulos A, Melachrinou M, Papageorgiou E, Fountzilas G: Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. Acta Haematol; 2005;113(2):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases.
  • The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization (WHO) classification of lymphoid neoplasms.
  • B cell lymphomas formed 88% of the cases whereas T cell lymphomas formed 12% of the total.
  • Indolent lymphomas accounted for 31.1%, aggressive ones for 66.7% and very aggressive ones for 2.4% of all NHLs.
  • Among indolent lymphomas extranodal ones (MALT B cell lymphoma) were the most common subset while follicular lymphoma grade I and II and small lymphocytic ones presented with equal frequency.
  • Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype; this entity along with large-cell immunoblastic lymphomas accounted for 45.2% of all B cell lymphomas.
  • Among the T cell lymphomas, peripheral T cell lymphomas and anaplastic large cell lymphomas of the T/null-cell type were the most common subtypes.
  • MALT B cell lymphomas were found in almost half of the patients with GI tract NHL, whereas in all other extranodal places DLCL was the predominant histological subtype.
  • This is the first report of a large series of malignant lymphomas in Greece using the WHO classification.
  • It appears that there are no significant differences between NHL in Greece and other large series as far as clinical and extranodal presentation is concerned.
  • The frequency of follicular lymphoma in the current study is comparable to that reported from Asian countries and mainland Europe, but lower than that of US and Northern European series.
  • [MeSH-major] Gastrointestinal Neoplasms / classification. Head and Neck Neoplasms / classification. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, T-Cell, Peripheral / classification

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 15802887.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Hsieh PP, Tseng HH, Chang ST, Fu TY, Lu CL, Chuang SS: Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan. Leuk Lymphoma; 2006 Jan;47(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare disorder representing less than 1% of all non-Hodgkin's lymphomas and has rarely been reported in Taiwan.
  • Eight cases (57%) were of B-cell phenotype and the remaining 6 (43%), T-cell.
  • Histologically, 7 (50%) were diffuse large B-cell lymphomas (DLBCLs) and 5 (36%) anaplastic large cell lymphomas.
  • Of the 11 patients with follow-up information, 6 (55%) died of disease within 1 year including 5 with T-cell lymphomas, while all the 5 patients surviving over 1 year were of B-cell phenotype.
  • The survival of B-cell lymphomas was significantly better than T-cell tumors (p = 0.016, log-rank test).
  • In summary, this study reported the largest series of PBL in Taiwan and confirmed that the majority was DLBCL and B-cell tumors had more favorable prognosis.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Lineage. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Phenotype. Predictive Value of Tests. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Kansal R, Sait SN, Block AW, Ward PM, Kelly FL, Cheney RT, Czuczman M, Brecher ML, Barcos M: Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology. Mod Pathol; 2005 Feb;18(2):235-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology.
  • The purpose of this study was to evaluate fluorescence in situ hybridization abnormalities of the 2p23 anaplastic lymphoma kinase (ALK) gene loci in lymphomas with anaplastic morphology.
  • We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/systemic (10 ALK+, 7 ALK-), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK+ B-lineage lymphoma, 14 ALK- diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30+), two follicular lymphomas].
  • ALK- lymphomas with anaplastic morphology showed extra nonrearranged anaplastic lymphoma kinase gene loci (P=0.004) due to trisomy 2 irrespective of the following factors: B or T/null phenotype (P=0.315), diagnostic categories of systemic or cutaneous ALCL or the above-mentioned B-cell lymphomas (P=0.131), and CD30 positivity by immunohistochemistry (P=1.000).
  • Trisomy 2 was absent in all ALK+ lymphomas (P=0.009), which showed rearranged ALK gene loci (P<0.001).
  • Whether trisomy 2 is a primary or secondary event that leads to ALK- lymphomas cannot be determined from this study.
  • Its presence in secondary B-cell lymphomas suggests that trisomy 2 may be a secondary cytogenetic aberration in lymphomas in general.
  • Further investigation of this finding is necessary to further our understanding of the heterogeneous group of ALK- lymphomas.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 2 / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Child. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Mucin-1 / analysis. Receptor Protein-Tyrosine Kinases. Statistics as Topic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475930.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


41. Perez-Pinera P, Garcia-Suarez O, Menendez-Rodriguez P, Mortimer J, Chang Y, Astudillo A, Deuel TF: The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun; 2007 Oct 12;362(1):5-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, PTN was found to activate anaplastic lymphoma kinase (ALK) through the PTN/RPTPbeta/zeta signaling pathway; this discovery potentially is very important, since constitutive ALK activity of nucleophosmin (NPM)-ALK fusion protein is causative of anaplastic large cell lymphomas, and, activated ALK is found in other malignant cancers.
  • RPTPbeta/zeta furthermore was localized not only in its normal association with the cell membrane but also scattered in cytoplasm and in nuclei in different breast cancer cells and, in the case of infiltrating ductal carcinomas, the distribution of RPTPbeta/zeta changes as the breast cancer become more malignant.

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2006 Feb;208(2):231-8 [16441567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12407-12 [16116087.001]
  • [Cites] FEBS Lett. 2006 Jul 24;580(17):4051-6 [16814777.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403 [17490616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6593-8 [11381105.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):162-71 [11795867.001]
  • [Cites] J Immunoassay Immunochem. 2002;23(1):33-48 [11848100.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):823-7 [11895915.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):858-63 [11953815.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2582-7 [1733956.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25889-97 [1464602.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1584-90 [7520350.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):309-14 [7533562.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16733-6 [9201975.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):537-43 [9389569.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1468-73 [9776412.001]
  • [Cites] Prostate. 1999 Feb 1;38(2):126-36 [9973098.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12474-9 [10212223.001]
  • [Cites] J Cutan Pathol. 2005 Feb;32(2):125-30 [15606670.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):637-43; discussion 644-5 [15684595.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 8;332(3):664-9 [15925565.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 16;335(1):232-9 [16105548.001]
  • [Cites] Neurosci Lett. 2006 May 15;399(1-2):33-8 [16513268.001]
  • (PMID = 17706593.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084400-06; United States / NCI NIH HHS / CA / R01 CA084400; United States / NIDDK NIH HHS / DK / T32 DK007022; United States / NCI NIH HHS / CA / R01 CA084400-06
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin; 137497-38-2 / midkine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / PTPRZ1 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  • [Other-IDs] NLM/ NIHMS30386; NLM/ PMC2084077
  •  go-up   go-down


42. Slack GW, Ferry JA, Hasserjian RP, Sohani AR, Longtine JA, Harris NL, Zukerberg LR: Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma; 2009 Jun;50(6):937-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis.
  • Lymphocyte depleted classical Hodgkin lymphoma (LDHL) is a vanishing category of classical Hodgkin lymphoma (CHL); many cases previously placed in this category are now recognised as diffuse large B-cell lymphoma (DLBCL), anaplastic large-cell lymphoma (ALCL), or nodular sclerosis CHL with lymphocyte depletion.
  • In addition, the recent recognition of high grade B-cell lymphomas intermediate between DLBCL and CHL (grey-zone lymphomas) raises the question of whether LDHL exists at all as a category of CHL.
  • In three cases the tumors had a more diffuse fibrotic appearance, while in five cases they appeared reticular and anaplastic.
  • Neoplastic cells in all cases expressed CD30, CD15, fascin, weak PAX5 and MUM-1 and lacked CD45, Alk-1, EMA, CD3, CD68, Mart-1 and cytokeratin.
  • Four cases were positive for EBV.
  • The combined morphologic, immunophenotypic and molecular genetic features of this group of cases distinguish LDHL from other disease entities, including grey-zone lymphomas.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphocytes / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD15 / analysis. Antigens, CD30 / analysis. B-Cell-Specific Activator Protein / analysis. Carrier Proteins / analysis. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Interferon Regulatory Factors / analysis. Male. Microfilament Proteins / analysis. Middle Aged. Polymerase Chain Reaction


43. Iyengar P, Reid-Nicholson M, Moreira AL: Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma. Diagn Cytopathol; 2006 Apr;34(4):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma.
  • Anaplastic large-cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults.
  • We herein report a case of ALCL arising in the breast of a 36-yr-old pregnant woman.
  • We would like to highlight the cytologic and histologic features of ALCL, as this case was initially misdiagnosed as a ductal carcinoma.
  • Differential diagnosis with other tumors is also discussed.
  • [MeSH-major] Breast / pathology. Carcinoma, Ductal, Breast / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pregnancy


44. Hernandez-Machin B, de Misa RF, Montenegro T, Rivero JC, Bastida J, Febles C, Pique E: MUM1 expression does not differentiate primary cutaneous anaplastic large-cell lymphoma and lymphomatoid papulosis. Br J Dermatol; 2009 Mar;160(3):713
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUM1 expression does not differentiate primary cutaneous anaplastic large-cell lymphoma and lymphomatoid papulosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Interferon Regulatory Factors / metabolism. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphomatoid Papulosis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans


45. Polgar D, Leisser C, Maier S, Strasser S, Rüger B, Dettke M, Khorchide M, Simonitsch I, Cerni C, Krupitza G: Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat Res; 2005 Feb 15;570(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chromosomal translocation t(2;5)(p23;q35) is associated with "Anaplastic large cell lymphomas" (ALCL), a Non Hodgkin Lymphoma occurring in childhood.
  • The fusion of the tyrosine kinase gene-ALK (anaplastic lymphoma kinase) on chromosome 2p23 to the NPM (nucleophosmin/B23) gene on chromosome 5q35 results in a 80 kDa chimeric protein, which activates the "survival" kinase PI3K.
  • This finding may be useful for the development of a new target-specific intervention.
  • [MeSH-minor] Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 5. Humans. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Protein Binding. Protein Structure, Tertiary. Receptor Protein-Tyrosine Kinases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680399.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


46. Asha LK, Thomas D, Binitha MP, Nandakumar G: Primary cutaneous multifocal CD30+ anaplastic large cell lymphoma. Indian J Dermatol Venereol Leprol; 2006 Sep-Oct;72(5):376-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous multifocal CD30+ anaplastic large cell lymphoma.
  • Biopsy and immunophenotyping revealed CD 30+ anaplastic primary cutaneous large cell lymphoma.
  • Primary cutaneous anaplastic large cell lymphoma is characterized by single or grouped reddish-brown tumor nodules, which frequently tend to ulcerate.
  • [MeSH-major] Antigens, CD30 / biosynthesis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / immunology. Skin Neoplasms / diagnosis. Skin Neoplasms / immunology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050936.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD30; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


47. Ng A, Hobson R, Williams D, Morland B: Anaplastic large cell lymphoma of bone--is it a bad tumor? Pediatr Blood Cancer; 2007 Apr;48(4):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma of bone--is it a bad tumor?
  • A teenage boy presented with a CD30-positive anaplastic large cell lymphoma (ALCL) affecting his scapula and was successfully treated with chemotherapy.
  • A further review of 11 ALCL cases with bony involvement treated in the UK since 1990, including two with primary bone disease, did not suggest an unfavorable treatment outcome.
  • This finding will need to be confirmed by further study on a larger patient cohort with primary bone ALCL.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Scapula / pathology
  • [MeSH-minor] Activin Receptors, Type II / analysis. Activin Receptors, Type II / genetics. Adolescent. Antigens, CD30 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Child. Child, Preschool. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Great Britain / epidemiology. Humans. Ifosfamide / administration & dosage. Infant. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078220.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 11
  •  go-up   go-down


48. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W: Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood; 2010 Apr 22;115(16):3314-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
  • Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ideal model disease to study tumor-specific immune responses.
  • Although antibodies and T-cell responses to ALK have previously been detected in ALK-positive ALCL patients, their prognostic significance is unknown.
  • We investigated a large cohort of uniformly treated ALK-positive pediatric ALCL patients to ascertain whether the titers of preexisting ALK autoantibodies correlated with clinical and histologic characteristics, tumor dissemination, and patient outcome.
  • Our results provide the first clinical evidence that a robust preexisting immune response to an oncoantigen resulting from an oncogenic chromosomal translocation inhibits lymphoma dissemination and decreases the risk of relapse.
  • [MeSH-major] Autoantibodies / immunology. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Recurrence, Local / immunology. Protein-Tyrosine Kinases / immunology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185586.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


49. Desouki MM, Post GR, Cherry D, Lazarchick J: PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res; 2010 Jul;8(2):84-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
  • OBJECTIVE: Undifferentiated tumors and hematolymphoid neoplasms can be diagnostically challenging due to potential overlap of morphologic features and variant antigen expression.
  • PAX-5, a transcription factor expressed throughout B-cell maturation, is detected in most B-cell neoplasms including those that lack expression of mature B-cell markers, such as classical Hodgkin lymphoma (cHL), B-lymphoblastic leukemia and B-cell lymphomas following rituximab therapy.
  • The lack of PAX-5 expression in most CD30-positive non-hematopoietic malignancies (embryonal carcinoma and seminoma) and T-cell lymphomas, such as anaplastic large cell lymphoma (ALCL), suggests that the absence of PAX-5 may be used to confirm non-B-cell lineage.
  • DESIGN: Diagnostic lymph node, decalcified core bone marrow biopsies and tissue sections from 111 archived paraffin-embedded tissue blocks and a tissue lymphoma microarray were immunostained using a monoclonal antibody to PAX-5.
  • PAX-5 immunoreactivity in neoplastic cells was scored as positive or negative.
  • RESULTS: Nuclear PAX-5 immunoreactivity was detected in 88% (36/41) of Hodgkin lymphoma, all cases of diffuse large B-cell lymphoma (n=72), small B-cell lymphomas (n=5), B-lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia with B-cell lineage (n=5).
  • PAX-5 was not detected in ALCL (n=22), T-cell lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia with T-cell lineage (n=5), acute myeloid leukemia (n=4), carcinoid tumors with typical morphology (n=5), melanoma (n=3), and undifferentiated/metastatic tumors (n=8).
  • Non-neoplastic bone marrow sections showed scattered nuclear staining in small B-cell lymphocytes/hematogones.
  • The detection of PAX-5 immunoreactivity resulted in the reclassification of two cases of ALCL to cHL.
  • CONCLUSION: Overall, our results demonstrate that including PAX-5 in a panel with other immunomarkers helps establish B-cell lineage and increases diagnostic yield.
  • [MeSH-major] B-Cell-Specific Activator Protein / analysis. Biomarkers, Tumor / analysis. Lymphoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hodgkin Disease / diagnosis. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Sep;114(4):881-3 [11564080.001]
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2335-41 [12613521.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4620-5 [12907641.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7399-404 [15492262.001]
  • [Cites] Genomics. 1991 Oct;11(2):424-34 [1685142.001]
  • [Cites] Blood. 1992 Jul 15;80(2):470-7 [1378322.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1589-607 [1516825.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):611-5 [10100713.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):32-8 [15628906.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):235-40 [16891199.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):534-44 [16938666.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1003-8 [17016584.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):798-804 [17050077.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Lab Invest. 2009 Mar;89(3):301-14 [19139719.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):775-80 [19145202.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • (PMID = 20660931.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC2910102
  •  go-up   go-down


50. Rekhi B, Sridhar E, Viswanathan S, Shet TM, Jambhekar NA: ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases. Acta Cytol; 2010 Jan-Feb;54(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases.
  • BACKGROUND: An accurate recognition of a lymphoma at an extranodal site is essential to avoid unnecessary excisions.
  • Fine needle aspiration cytology (FNAC) has been recognized as a useful tool in the primary diagnosis of soft tissue tumors.
  • An anaplastic large cell lymphoma (ALCL), occurring in soft tissues, poses a diagnostic challenge.
  • We present the cytomorphology of 2 cases of anaplastic lymphoma kinase (ALK)+ ALCL that displayed a perivascular arrangement, thereby mimicking a sarcoma.
  • Differential diagnoses included a rhabdomyosarcoma and a lymphoma.
  • On biopsy and immunohistochemistry, tumor cells were positive for vimentin, LCA, EMA, CD30 and ALK.
  • CONCLUSION: ALCL should be considered in the differential diagnosis of pediatric soft tissue tumors, especially in cases with multifocal involvement.
  • [MeSH-major] Biopsy, Fine-Needle. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Receptor Protein-Tyrosine Kinases. Sarcoma / pathology


51. Buxton D, Bacchi CE, Gualco G, Weiss LM, Zuppan CW, Rowsell EH, Huang Q, Wang J: Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. Am J Clin Pathol; 2009 Apr;131(4):574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases.
  • By using conventional paraffin immunoperoxidase staining and tissue microarrays, we retrospectively investigated CD99 expression in a series of 160 anaplastic large cell lymphoma (ALCL) cases.
  • Of the 160 cases, 103 (64.4%) were positive for CD99.
  • CD99 expression was present in 96 (64.4%) of 149 of the common type, 4 (80%) of 5 of the small cell variant, and 3 (50%) of 6 of the lymphohistiocytic variant cases.
  • CD99 expression was slightly more frequent in anaplastic large cell lymphoma kinase (ALK)+ cases compared with ALK- cases (43/54 [80%] vs 44/81 [54%]).
  • With 2 exceptions, ALK+ ALCL was seen only in patients younger than 41 years.
  • We conclude that CD99 is frequently expressed in ALCL, with a slightly increased frequency in the younger age ALK+ cases.
  • Nodal and extranodal ALCL should be considered in the differential diagnosis when a CD99+ neoplasm is encountered.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / biosynthesis. Lymphoma, Large-Cell, Anaplastic / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289593.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


52. Sharma PK, He M, Jurayj J, Gou DM, Lombardy R, Romanczyk LJ Jr, Schroeter H: Enantioselctive syntheses of sulfur analogues of flavan-3-Ols. Molecules; 2010 Aug;15(8):5595-619
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The key steps were: (a) Pd(0) catalyzed introduction of -S t-butyl group, (b) Sharpless enantioselective dihydroxylation of the alkene, (c) acid catalyzed ring closure to produce the thiopyran ring, and (d) removal of benzyl groups using N,N-dimethylaniline and AlCl(3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714315.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Sulfur Compounds; 0 / flavan-3-ol
  •  go-up   go-down


53. Lund CL, Schachner JA, Burgess IJ, Quail JW, Schatte G, Müller J: Synthesis and characterization of aluminum- and gallium-bridged [1.1]chromarenophanes and [1.1]molybdarenophanes. Inorg Chem; 2008 Jul 7;47(13):5992-6000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A salt-metathesis reaction of [2-(Me 2NCH 2)C 6H 4]AlCl 2 with freshly prepared [Cr(LiC 6H 5) 2].TMEDA (TMEDA = N, N, N', N'-tetramethylethylenediamine) resulted in the dialumina[1.1]chromarenophane [{2-(Me 2NCH 2)C 6H 4}Al(eta (6)-C 6H 5) 2Cr] 2 ( 2a).
  • Salt-metathesis reactions of 3a and 3b, respectively, with freshly prepared [M(LiC 6H 5) 2].TMEDA (M = Cr, Mo) resulted in four new [1.1]metallarenophanes of the general type [{5- tBu-2-(Me 2NCH 2)C 6H 3}E(eta (6)-C 6H 5) 2M] 2 [E = Al, M = Cr ( 4a); E = Ga, M = Cr ( 4b); E = Al, M = Mo ( 5a); E = Ga, M = Mo ( 5b)].

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533628.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Erdogan-Orhan I, Sever-Yılmaz B, Altun ML, Saltan G: Radical quenching activity, ferric-reducing antioxidant power, and ferrous ion-chelating capacity of 16 Ballota species and their total phenol and flavonoid contents. J Med Food; 2010 Dec;13(6):1537-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total phenol and flavonoid contents of the extracts were determined by Folin-Ciocalteau and AlCl(3) reagents, respectively.
  • The extracts showed insignificant quenching activity against DPPH radical, but they had moderate antioxidant activity (0.597 ± 0.03 to 1.342 ± 0.01) in the ferric-reducing test compared to chlorogenic acid (the reference compound) (3.618 ± 0.01).

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091260.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Diterpenes; 0 / Flavonoids; 0 / Food Preservatives; 0 / Free Radical Scavengers; 0 / Iron Chelating Agents; 0 / Phenols; 0 / Plant Extracts; 0 / Solvents; 0 / hispanolone
  •  go-up   go-down


55. Tripathi S, Mahdi AA, Nawab A, Chander R, Hasan M, Siddiqui MS, Mahdi F, Mitra K, Bajpai VK: Influence of age on aluminum induced lipid peroxidation and neurolipofuscin in frontal cortex of rat brain: a behavioral, biochemical and ultrastructural study. Brain Res; 2009 Feb 9;1253:107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The markers of oxidative stress, e.g. lipid peroxides and endogenous antioxidants as well as metals (Al, Fe, Cu, Zn and Se) were measured in the brain frontal cortex of young and aged rats fed with AlCl(3) (100 mg/kg b.w.) for 90 days and normal saline treated controls.
  • On the basis of the results of the present study, we conclude that Al may be linked with neurolipofuscinogenesis and alteration in neurobehavioral activity and these changes may be responsible for the development of age related disorders, such as Alzheimer's disease.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073157.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Antioxidants; 0 / Chlorides; 0 / Lipid Peroxides; 0 / Lipofuscin; 0 / Metals, Heavy; 3CYT62D3GA / aluminum chloride; H6241UJ22B / Selenium
  •  go-up   go-down


56. Chiu LS, Choi PC, Luk NM, Chang M, Tang WY: Spontaneous regression of primary cutaneous Epstein-Barr virus-positive, CD30-positive anaplastic large T-cell lymphoma in a heart-transplant recipient. Clin Exp Dermatol; 2009 Jul;34(5):e21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of primary cutaneous Epstein-Barr virus-positive, CD30-positive anaplastic large T-cell lymphoma in a heart-transplant recipient.
  • We presented a rare case of primary cutaneous Epstein-Barr virus-positive, CD30-positive anasplastic large cell lymphoma in a 64-year-old man who had received a heart transplant 11 years previously.
  • There was no recurrence 9 months after the first diagnosis.
  • We propose that dose reduction of immunosuppressant alone may be an effective treatment for localized, indolent, post-transplant-related primary cutaneous lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Heart Transplantation / immunology. Lymphoma, Large-Cell, Anaplastic / virology. Neoplasm Regression, Spontaneous / immunology. Skin Neoplasms / virology


57. Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol; 2008 Aug;87(8):613-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies.
  • Fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in Hodgkin and B-cell lymphomas.
  • Few data exist on T-cell and natural killer (NK)-cell lymphomas.
  • Thirty consecutive T-cell and NK-cell lymphomas were investigated with PET-computerized tomography (CT).
  • In 12 NK-cell lymphomas, all nasal/extranasal lesions were FDG-avid.
  • In two NK-cell lymphomas, PET did not detect morphologically occult marrow infiltration uncovered by in situ hybridisation for Epstein-Barr-virus-encoded small RNA.
  • In angioimmunoblastic lymphoma (n = 7), peripheral T-cell lymphoma, unspecified (PTCL-U, n = 4) and anaplastic large cell lymphoma (ALCL, n = 3), involved nodal/extranodal sites shown on CT and/or biopsy were concordantly PET-positive.
  • In contrast, cutaneous ALCL (n = 1) and mycosis fungoides (n = 2) showed minimal FDG uptake.
  • In one case of T-cell large granular lymphocyte leukaemia, marrow, nodal and bowel infiltrations were not FDG-avid.
  • These observations defined the pre-treatment value of PET-CT in T-cell and NK-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / radionuclide imaging. Lymphoma, T-Cell / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease Progression. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509641.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • Most CNS-positive patients with pB-LBL, T-LBL, or BL/B-ALL had meningeal disease.
  • For the 112 CNS-positive patients, pEFS was 64% +/- 5%, compared with 86% +/- 1% for the 1,927 CNS-negative patients (P < .001).
  • Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001).
  • In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Nowak J, Friend AL: Loblolly pine and slash pine responses to acute aluminum and acid exposures. Tree Physiol; 2006 Sep;26(9):1207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each species was exposed to a single soil application of aluminum chloride (0.33 M AlCl(3), pH 2.5), hydrochloric acid (0.39 M HCl, pH 0.6) or water, with or without mycorrhizal inoculation with Pisolithus tinctorius (Coker and Couch).
  • After 20 weeks without inoculation, survival in AlCl(3) and HCl treatments averaged 52% for loblolly pine and 72% for slash pine.
  • Inoculation also resulted in improved survival and growth of individual families in AlCl(3), but not in HCl treatments.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740496.001).
  • [ISSN] 0829-318X
  • [Journal-full-title] Tree physiology
  • [ISO-abbreviation] Tree Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Soil; 3CYT62D3GA / aluminum chloride; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


60. Li D, Li GD, Liu WP, Li FY, Zhang WY, Liao DY: [Expression of B cell-specific activator protein in lymphomas]. Zhonghua Bing Li Xue Za Zhi; 2005 Jun;34(6):345-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of B cell-specific activator protein in lymphomas].
  • OBJECTIVE: To investigate the expression of B cell-specific activator protein (BSAP)/Pax-5 in lymphomas.
  • METHODS: One hundred and two cases of diffuse large B-cell lymphoma (DLBCL), 3 cases of follicular lymphoma (FL), 3 cases of extranodal marginal zone B-cell lymphoma, 1 case of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 10 cases of anaplastic large cell lymphoma (ALCL) and 10 cases of plasmacytoma were studied immunohistochemically for BSAP and CD20.
  • Three cases of FL, 3 cases of extranodal marginal zone B-cell lymphoma and 1 case of NLPHL also expressed BSAP and CD20.
  • All the ALCLs and plasmacytomas did not express BSAP and CD20.
  • CONCLUSIONS: BSAP/Pax-5 is a novel B-cell marker expressed in tumor nuclei of B-cell lymphomas.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Biomarkers, Tumor. Cell Nucleus / metabolism. Child. Child, Preschool. Female. Humans. Lymphoma, Follicular / metabolism. Male. Middle Aged. Plasmacytoma / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185503.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Larsen SR, Rasko JE: Lymphoproliferative disorders: prospects for gene therapy. Pathology; 2005 Dec;37(6):523-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymphoproliferative disorders represent a large group of diseases with a significant variation in presentation and clinical course.
  • Methods to improve gene delivery efficiency have been the focus of a large amount of research and to date the optimal procedure uses viruses such as oncoretroviruses, lentiviruses, adenoviruses, adeno-associated viruses and herpes simplex viruses.
  • First, immunotherapy using tumour vaccines or techniques to enhance the function of immune effector cells has been investigated with some success in patients with B-cell malignancies.
  • Second, the introduction of prodrug-activated 'suicide' genes into cells has been explored, in particular in patients with post-transplantation lymphoproliferative disease.
  • Third, direct lysis of tumour cells using viruses shows some early promise, especially in the treatment of B-cell disorders by manipulating the measles virus to target the CD20 antigen.
  • RNA interference in particular has tremendous potential and has been studied in the context of anaplastic large cell lymphoma as well as Epstein-Barr virus-associated malignancies.
  • [MeSH-minor] Animals. Clinical Trials as Topic. Disease Models, Animal. Gene Transfer Techniques. Humans. RNA Interference. RNA, Small Interfering / therapeutic use

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373231.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Number-of-references] 107
  •  go-up   go-down


62. Mergan F, Jaubert F, Sauvat F, Hartmann O, Lortat-Jacob S, Révillon Y, Nihoul-Fékété C, Sarnacki S: Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Pediatr Surg; 2005 Oct;40(10):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis.
  • Differential diagnosis with other tumor processes is sometimes difficult.
  • Similar anaplastic lymphoma kinase (ALK) gene abnormalities as in anaplastic large cell lymphoma have been reported.
  • ALK was positive in 3 (18.8%) cases and EBV in 1 pulmonary and 1 bladder tumor, all of them without recurrence or metastasis.
  • None of the cases were positive for HHV-8.
  • All patients are now disease-free with a mean follow-up of 4.2 years.
  • [MeSH-major] Granuloma, Plasma Cell / enzymology. Granuloma, Plasma Cell / virology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226988.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


63. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • Most circulating human B cells and a small subset of T cells are BAFF-R-positive.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


64. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer; 2005 Nov;45(6):753-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
  • Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma.
  • The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology


65. Madray MM, Greene JF Jr, Butler DF: Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol; 2008 Oct;65(10):1378-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
  • OBJECTIVE: To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.
  • Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma.
  • Further evaluation showed no systemic involvement.
  • CONCLUSIONS: Several T-cell-mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum.
  • We report the association of a T-cell malignancy with the use of glatiramer acetate.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Leg / pathology. Lymphoma, Large-Cell, Anaplastic / chemically induced. Peptides / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antigens, CD30 / biosynthesis. Biomarkers. Biopsy. Female. Glatiramer Acetate. Humans. Multiple Sclerosis, Relapsing-Remitting / drug therapy. Neoplasm, Residual. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852356.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate
  •  go-up   go-down


66. De Nisi MC, D'Amuri A, Lalinga AV, Occhini R, Biagioli M, Miracco C: Posttransplant primary cutaneous CD30 (Ki-1)-positive anaplastic large T-cell lymphoma. A case report. Br J Dermatol; 2005 May;152(5):1068-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant primary cutaneous CD30 (Ki-1)-positive anaplastic large T-cell lymphoma. A case report.
  • [MeSH-major] Heart Transplantation / adverse effects. Lymphoma, Large-Cell, Anaplastic / etiology. Skin Neoplasms / etiology


67. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L: Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A; 2010 Sep 14;107(37):16228-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
  • Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma.
  • We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK.
  • Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL.
  • Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL.
  • Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins.
  • Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / enzymology. Lymphoma, Large-Cell, Anaplastic / genetics. MicroRNAs / genetics. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Base Sequence. Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Mice. Mice, Transgenic. Multigene Family. Receptor Protein-Tyrosine Kinases. Sirolimus / analogs & derivatives. Sirolimus / therapeutic use. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Blood. 1988 Sep;72(3):1045-7 [3416066.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] FASEB J. 1997 Oct;11(12):965-72 [9337149.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Nat Med. 2005 Jun;11(6):623-9 [15895073.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1131-3 [16082218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6589-97 [16818631.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3275-9 [17094440.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1621-30 [17416736.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3374-83 [17690253.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Cell. 2008 Apr 18;133(2):217-22 [18423194.001]
  • [Cites] J Virol. 2008 Sep;82(18):9065-74 [18596100.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1135-42 [19155302.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2623-9 [19258506.001]
  • [Cites] Circ Res. 2009 May 22;104(10):1184-91 [19390056.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1585-95 [19531656.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1466-76 [19737969.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2129-38 [19657361.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1583-90 [20159827.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2309-10 [12057933.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):875-83 [12213716.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):517-27 [12555065.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] J Immunol. 1980 Feb;124(2):879-84 [7188701.001]
  • [Cites] Blood. 1988 Jul;72(1):234-40 [3260522.001]
  • [Cites] Blood. 2010 May 27;115(21):4191-7 [20089965.001]
  • (PMID = 20805506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / V 102
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MicroRNAs; 624KN6GM2T / temsirolimus; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2941277
  •  go-up   go-down


68. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Führer M, Kühne T, Parwaresch R, Ebell W, Reiter A: Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. Br J Haematol; 2006 Apr;133(2):176-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
  • Patients with refractory or early relapsed anaplastic large cell lymphoma (ALCL) have a poor chance of survival.
  • We report 20 children and adolescents with high-risk relapsed or refractory ALCL who underwent allogeneic haematopoietic stem cell transplantation (HSCT).
  • We retrospectively analysed 20 patients who relapsed between December 1991 and April 2003 during (six patients) or soon after first-line Berlin-Frankfurt-Münster-type chemotherapy (14 patients) and underwent allogeneic HSCT.
  • There was no influence of donor type or conditioning regimen on outcome.
  • Two of six patients with progressive disease during frontline therapy survived compared with 13/14 patients with a first relapse after frontline therapy.
  • Two of three patients who were transplanted with active lymphoma and all five patients who received allogeneic HSCT for relapse following autologous HSCT survived disease-free.
  • Allogeneic HSCT is effective and has acceptable toxicity as rescue therapy for high-risk ALCL relapse.
  • It even offers cure for patients refractory to chemotherapy, suggesting a graft-versus-ALCL effect.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Large-Cell, Anaplastic / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease Progression. Drug Resistance, Neoplasm. Epidemiologic Methods. Female. Graft vs Host Disease / prevention & control. Humans. Male. Recurrence. Transplantation Conditioning / methods. Treatment Outcome


69. Marschalkó M, Eros N, Holló P, Hársing J, Bottlik G, Bátai A, Csukly Z, Masszi T, Szentirmai Z, Fodor J, Kárpáti S, Matolcsy A, Csomor J: Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. Am J Dermatopathol; 2010 Oct;32(7):708-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.
  • At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed.
  • Four years later, systemic relapse was detected which was refractory to therapy.
  • Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells.
  • Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples.
  • The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily.
  • Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology


70. Zhang L, Wu G: Complete atelectasis of the left lung from anaplastic large-cell lymphoma. ScientificWorldJournal; 2010;10:1332-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete atelectasis of the left lung from anaplastic large-cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / complications. Pulmonary Atelectasis / etiology


71. Bishu S, Quigley JM, Schmitz J, Bishu SR, Stemm RA, Olsasky SM, Paknikar S, Holdeman KH, Armitage JO, Hankins JH: F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma; 2007 Aug;48(8):1531-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas.
  • F-18-fluoro-deoxy-glucose positron emission tomography (PET) is highly sensitive and specific in the imaging of B-cell lymphomas.
  • In contrast, its utility in the diagnostic evaluation of T-cell lymphomas is less defined.
  • In this article, we present our finding utilizing PET in peripheral T-cell lymphomas (PTCL).
  • PET findings were compared with a standard of reference and sensitivity, specificity, positive and negative predictive values were calculated.
  • The mean SUV of abnormal foci in anaplastic large cell lymphoma was 11 mg/ml (range: 3 - 40), and PTCL-unclassified was 8 mg/ml (range: 1 - 23).
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, T-Cell, Peripheral / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / radiography. Lymphoma, T-Cell, Cutaneous / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Aug;48(8):1465-7 [17701574.001]
  • (PMID = 17701584.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Shimizu Y, Tanae K, Takahashi N, Kohri M, Arai E, Bessho M, Niitsu N: Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res; 2010 Feb;34(2):263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature.
  • Primary cutaneous anaplastic large-cell lymphoma (C-ALCL) is a rare entity of lymphoma.
  • We report a case of C-ALCL presenting with hemophagocytic syndrome and skin lesion with giant ulcer.
  • Histopathological examination of the skin biopsy specimens showed non-epidermotropic infiltrates with cohesive sheets of large tumor cells.
  • The tumor cells showed CD4-, CD8+, CD30+, CD56-, ALK-, TIA-1+, and granzyme B+.
  • C-ALCL is generally a disorder that progresses slowly and has a good prognosis.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Skin Ulcer / etiology
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19640585.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


73. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol; 2007 Jul 1;25(19):2764-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
  • PURPOSE: MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models.
  • To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed.
  • Twenty-one patients--16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell lymphoma--were enrolled.
  • In the phase II portion, an additional 51 patients, 47 with HL and four with ALCL, were treated at doses of 1, 5, 10, and 15 mg/kg.
  • Twenty-five patients had stable disease, including five who remained free from progression 1 year after treatment.
  • MDX-060 has limited activity as a single agent, but the minimal toxicity observed and the significant proportion of patients with stable disease suggests that further study of MDX-060 in combination with other therapies is warranted.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Hodgkin Disease / therapy. Immunotherapy / methods. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / iratumumab
  •  go-up   go-down


74. Mandujano-Alvarez GJ, Moreno-Sánchez F, Morales-Polanco M, García-Ortiz JR, Ortiz-Hidalgo C: [Primary bone anaplastic large cell lymphoma]. Acta Ortop Mex; 2009 May-Jun;23(3):142-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary bone anaplastic large cell lymphoma].
  • [Transliterated title] Linfoma anaplásico de células grandes. Primario de hueso.
  • INTRODUCTION: Anaplastic large cell lymphoma (ALCL) is a neoplasia of T-cell or null-cell origin accounting for approximately 3% of non-Hodgkin lymphomas in adults and 10-30% of lymphomas in children.
  • CASE REPORT: A 47-year-old male presented with an ALCL and multiple bone lesions involving the vertebrae, ribs, and iliac bone, with no other site of involvement.
  • Histologic findings included interstitial and focal bone infiltrate consisting of large pleomorphic cells with an inflammatory background and marked fibrosis.
  • There was immunohistochemical expression of CD30, EMA, CD45RO, CD43, CD8, Glut-1 and ALK-1.
  • DISCUSSION: There are 20 reported cases of ALCL (T/null cell) arising from the bone.
  • To diagnose primary bone lymphoma it is necessary to first exclude systemic lymphoma of the lymph nodes or the skin with bone spread.
  • The differential diagnoses include osteomyelitis, small round cell tumors, mainly Ewing sarcoma/PNET, metastatic carcinoma, melanoma, Hodgkin lymphoma and Langerhans' cell histiocytosis.
  • [MeSH-major] Bone Neoplasms. Lymphoma, Large-Cell, Anaplastic


75. Wang Y, Gao BY, Xu XM, Xu WY, Xu GY: Characterization of floc size, strength and structure in various aluminum coagulants treatment. J Colloid Interface Sci; 2009 Apr 15;332(2):354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different Al coagulants--conventional Al salt (AlCl(3)), polyaluminum chloride (PAC-1) and the purified polyaluminum chloride (PAC-2)--were investigated for the coagulation of humic acid (HA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185875.001).
  • [ISSN] 1095-7103
  • [Journal-full-title] Journal of colloid and interface science
  • [ISO-abbreviation] J Colloid Interface Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Li D, Li GD, Liu WP, Zhang WY, Li FY, Liao DY: [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas]. Zhonghua Xue Ye Xue Za Zhi; 2005 Apr;26(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas].
  • OBJECTIVE: To explore the prognostic factors of primary nodal diffuse large B-cell lymphomas (N-DLBCL).
  • Antibodies used for study were anti-CD20, CD79alpha, CD45RO, CD3, Bcl-2, Ki-67, CD30, CD15, kappa, lambda, Cyclin D1, TdT, GFAP, CK, MPO.
  • RESULTS: Of the 51 cases of N-DLBCLs, 40 were reclassified as centroblastic, 3 B-immunoblastic, 1 T-cell/histiocytes rich, 2 B-cell anaplastic large cell, 1 plasmablastic, and 4 unclassified.
  • The median Ki-67 index was 50.0% and the index more than 40% was found in 35 cases (68.6%).
  • The 5-year OS rates patients with International Prognosis Index (IPI) >/= 3 was lower than that with IPI < 3 (P < 0.01).
  • The 5-year OS rates for patients with Ki-67 index more than 40% was lower than that with less than 40% (P < 0.05).
  • CONCLUSION: IPI, B symptoms and Ki-67 index are the prognostic factors for patients with N-DLBCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Cyclin D1 / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Prognosis. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949265.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


77. zur Nieden NI, Baumgartner L: Assessing developmental osteotoxicity of chlorides in the embryonic stem cell test. Reprod Toxicol; 2010 Sep;30(2):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing developmental osteotoxicity of chlorides in the embryonic stem cell test.
  • This study employs the embryonic stem cell test to unambiguously characterize the effect of four chlorides with increasing valence, NaCl, LiCl, MgCl(2) and AlCl(3), utilizing the capacity of murine embryonic stem cells to differentiate into bone forming cells in vitro.
  • Although this effect was clearer for AlCl(3) than for the other tested chlorides, we suggest extreme caution should still be given when administering any chloride during pregnancy.
  • [MeSH-minor] Animal Testing Alternatives / methods. Animals. Cell Differentiation / drug effects. Cell Line. Cell Survival / drug effects. Dose-Response Relationship, Drug. Mice. Osteogenesis / drug effects. Osteogenesis / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20447454.001).
  • [ISSN] 1873-1708
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorides; 0 / Teratogens
  •  go-up   go-down


78. Marschalkó M, Csomor J, Eros N, Szigeti A, Hársing J, Szakonyi J, Désaknai M, Matolcsy A, Demeter J, Kárpáti S: Coexistence of primary cutaneous anaplastic large cell lymphoma and mycosis fungoides in a patient with B-cell chronic lymphocytic leukaemia. Br J Dermatol; 2007 Dec;157(6):1291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of primary cutaneous anaplastic large cell lymphoma and mycosis fungoides in a patient with B-cell chronic lymphocytic leukaemia.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mycosis Fungoides / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


79. Jyoti A, Sethi P, Sharma D: Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol; 2007 Apr 20;111(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Male Wister rats (8 months old) were administered with AlCl(3) orally at a dose of 50mg/kg/day in drinking water for 1 month.
  • Experimental rats were given AlCl(3) along with Bacopa monniera extract at a dose of 40 mg/kg/day.
  • One group of rats was treated with l-deprenyl at a dose of 1mg/kg/day along with AlCl(3) treatment.
  • [MeSH-minor] Aldehydes / metabolism. Aluminum Compounds. Animals. Chlorides. Disease Models, Animal. Glutathione / metabolism. Glutathione Peroxidase / metabolism. Glutathione Transferase / metabolism. India. Male. Medicine, Ayurvedic. Plant Extracts / pharmacology. Protein Carbonylation / drug effects. Rats. Rats, Wistar. Selegiline / pharmacology. Superoxide Dismutase / metabolism. Thiobarbituric Acid Reactive Substances / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELEGILINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189676.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Aluminum Compounds; 0 / Antioxidants; 0 / Chlorides; 0 / Neuroprotective Agents; 0 / Plant Extracts; 0 / Thiobarbituric Acid Reactive Substances; 29343-52-0 / 4-hydroxy-2-nonenal; 2K1V7GP655 / Selegiline; 3CYT62D3GA / aluminum chloride; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione
  •  go-up   go-down


80. Vidovic D, Reeske G, Findlater M, Cowley AH: Synthesis and structures of boron dihalides supported by the C(6)F(5)-substituted beta-diketiminate ligand [HC(CMe)(2)(NC(6)F(5))(2)](-). Dalton Trans; 2008 May 7;(17):2293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new boron dihalides of the type [HC(CMe)(2)(NC(6)F(5))(2)]BX(2) (X = Cl, Br, I) have been prepared and characterized by single-crystal X-ray diffraction.
  • Chloroborenium salt [HC(CMe)(2)(NC(6)F(5))(2)BCl][AlCl(4)] was prepared by treatment of [HC(CMe)(2)(NC(6)F(5))(2)]BCl(2) with AlCl(3) in CH(2)Cl(2) solution.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414754.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Jiang HX, Tang N, Zheng JG, Li Y, Chen LS: Phosphorus alleviates aluminum-induced inhibition of growth and photosynthesis in Citrus grandis seedlings. Physiol Plant; 2009 Nov;137(3):298-311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sour pummelo (Citrus grandis) seedlings were irrigated for 18 weeks with nutrient solution containing 50, 100, 250 and 500 microM KH(2)PO(4)x 0 and 1.2 mM AlCl(3). 6H(2)O.

  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832942.001).
  • [ISSN] 1399-3054
  • [Journal-full-title] Physiologia plantarum
  • [ISO-abbreviation] Physiol Plant
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosystem I Protein Complex; 0 / Photosystem II Protein Complex; 1406-65-1 / Chlorophyll; 142M471B3J / Carbon Dioxide; 27YLU75U4W / Phosphorus; CPD4NFA903 / Aluminum; EC 4.1.1.39 / Ribulose-Bisphosphate Carboxylase
  •  go-up   go-down


82. Kempf W, Kutzner H, Cozzio A, Sander CA, Pfaltz MC, Müller B, Pfaltz M: MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol; 2008 Jun;158(6):1280-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
  • BACKGROUND: Primary cutaneous CD30+ lymphoproliferative disorders include lymphomatoid papulosis (LyP) and primary cutaneous CD30+ anaplastic large T-cell lymphoma (ALCL).
  • Because of overlapping histological features, it is impossible to distinguish ALCL from LyP on histological grounds.
  • MUM1 (Multiple Myeloma oncogene 1) is expressed in systemic ALCL and classical Hodgkin lymphoma.
  • MUM1 expression has not been studied in detail in CD30+ lymphoproliferative disorders.
  • OBJECTIVES: To examine the expression of MUM1 in CD30+ lymphoproliferative disorders and to assess its value as a diagnostic marker.
  • METHODS: Thirty-one formalin-fixed paraffin-embedded specimens of LyP (n = 15), primary cutaneous ALCL (n = 10), secondary cutaneous infiltrates of systemic ALCL (n = 4) and secondary cutaneous Hodgkin lymphoma (n = 2) were analysed by immunohistochemistry with a monoclonal antibody against MUM1.
  • RESULTS: Positive staining for MUM1 was observed in 13 cases of LyP (87%), two cases of primary cutaneous ALCL (20%), four cases of secondary cutaneous ALCL (100%) and two cases of secondary cutaneous Hodgkin lymphoma (100%).
  • In contrast to LyP and secondary cutaneous ALCL, only two cases of primary cutaneous ALCL (20%) harboured MUM1-positive tumour cells.
  • There was a statistically significant difference in the expression of MUM1 between LyP and primary cutaneous ALCL (P = 0.002) and between primary cutaneous ALCL and secondary cutaneous ALCL (P = 0.015).
  • CONCLUSIONS: MUM1 expression is a valuable tool for the distinction of LyP and ALCL and thus represents a novel adjunctive diagnostic marker in CD30+ lymphoproliferative disorders.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Interferon Regulatory Factors / metabolism. Lymphoproliferative Disorders / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / metabolism. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism


83. Kushkuley J, Metkar S, Chan WK, Lee S, Shea TB: Aluminum induces neurofilament aggregation by stabilizing cross-bridging of phosphorylated c-terminal sidearms. Brain Res; 2010 Mar 31;1322:118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined their formation and reversibility under cell-free conditions.
  • CaCl(2)-induced dimers and AlCl(3)-induced aggregates were prevented by prior NF dephosphorylation.
  • While CaCl(2)-induced dimers were dissociated by phosphatase treatment, AlCl(3)-induced aggregates were only reduced by approximately 50%, suggesting that aggregates may sequester phosphorylation sites.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CALCIUM CHLORIDE .
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier B.V.
  • (PMID = 20132798.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Neurofilament Proteins; 0 / Neurotoxins; 3CYT62D3GA / aluminum chloride; CPD4NFA903 / Aluminum; M4I0D6VV5M / Calcium Chloride
  •  go-up   go-down


84. Belousova IE, Kazakov DV, Sosna B, Sulc M, Michal M: [Small-cell variant of CD30+ -anaplastic large-cell lymphoma of the skin]. Arkh Patol; 2008 Mar-Apr;70(2):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small-cell variant of CD30+ -anaplastic large-cell lymphoma of the skin].
  • Three cases of the so-called variant of primary cutaneous CD30+ anaplastic large cell lymphoma (ALCL) are presented.
  • Microscopically, the tumors were composed of small cells with irregular nuclei that were immunohistochemically positive for CD3, CD5, CD7, and CD30 and negative for B-cell markers; there was focal ALK-1 positivity in 1 case.
  • Fhedium to large CD30+ cells were rarely found scattered in the infiltrate.
  • Chemotherapy was performed and finally the patient underwent allogenic bone marrow transplantation; he died 3 years after the original diagnosis due to acute graft-versus-host disease and sepsis.
  • [MeSH-major] Antigens, CD30. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD / immunology. Cell Size. Gene Rearrangement, B-Lymphocyte / immunology. Gene Rearrangement, T-Lymphocyte / immunology. Humans. Immunoglobulin Heavy Chains / immunology. Male. Middle Aged. Receptors, Antigen, T-Cell / immunology


85. Huang W, Li X, Yao X, Lu Y, Li B, Sheng W, Lu H, Jin A, Zhou X: Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma. Exp Mol Pathol; 2009 Apr;86(2):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma.
  • Systemic anaplastic large cell lymphoma (ALCL) can be divided into two subgroups, anaplastic lymphoma kinase (ALK)-positive and ALK-negative, based on the expression of ALK protein.
  • In this study, we investigated the expression of ALK protein, mRNA and fusion transcripts involving ALK and their relationships in ALCL and analyzed formalin-fixed, paraffin-embedded tissues.
  • Our results showed that the expression of ALK protein, ALK mRNA and ALK fusion transcripts were significantly related to one another (P<0.01).
  • Consistent with the expression of ALK protein, patients presenting with ALK mRNA or ALK involved fusion transcripts were significantly younger than those lacking ALK gene alteration (P<0.01).
  • Combined detection of ALK protein, ALK mRNA and ALK fusion transcripts can complement each other to aid in the diagnosis of ALCL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / enzymology. Lymphoma, Large-Cell, Anaplastic / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135051.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


86. Khamaysi Z, Ben-Arieh Y, Izhak OB, Epelbaum R, Dann EJ, Bergman R: The applicability of the new WHO-EORTC classification of primary cutaneous lymphomas to a single referral center. Am J Dermatopathol; 2008 Feb;30(1):37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The applicability of the new WHO-EORTC classification of primary cutaneous lymphomas to a single referral center.
  • Recent years have witnessed differences between the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC) classification systems of primary cutaneous lymphomas (PCLs).
  • There were 43 new non-mycosis fungoides/Sezary syndrome PCLs, including 29 B-cell lymphomas of which 14 were follicle center lymphoma, 10 marginal zone lymphoma, 4 diffuse large-B-cell lymphoma, leg type, and 1 diffuse large-B-cell lymphoma, other.
  • The 14 T-cell lymphomas included 5 cases of lymphomatoid papulosis, 2 CD30+ anaplastic large-cell lymphomas, 1 NK/T-cell lymphoma, and 6 peripheral T-cell lymphomas, unspecified.
  • Of the 6 "unspecified" T-cell lymphomas, 3 were CD4+ small/medium-sized pleomorphic T-cell lymphoma, which is considered currently a provisional entity under the unspecified T-cell category.
  • The remaining 3 cases could not be classified beyond the unspecified T-cell category, of which 2 cases had an aggressive course.
  • The new WHO-EORTC classification is applicable to most non-mycosis fungoides/Sezary syndrome PCL cases, especially the B-cell lymphomas.
  • However, there is still a substantial subset of T-cell PCLs which cannot be classified beyond the unspecified peripheral T-cell category, some of which may have an aggressive course.
  • [MeSH-major] Lymphoma / classification. Skin Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212543.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Tamaru J, Tokuhira M, Nittsu N, Nakamura S, Ichinohasama R, Suzuki R, Mori H, Takagi T, Suzuki T, Itami J, Itoyama S, Mikata A: Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1127-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma.
  • In the WHO classification, the majority of Hodgkin-like ALCL cases as defined by the REAL classification are considered to be CHL.
  • However, establishing a histological diagnosis for the gray zone between CHL and ALCL is often confusing.
  • Expression of PAX-5/BSAP was observed in 88% (76/87) of CHL specimens and none (0/11) of ALK-positive ALCL specimens.
  • Among specimens of Hodgkin-like ALCL and ALK-negative ALCL, expression of PAX-5/BSAP was observed in 77% (20/26) and 18% (3/17), respectively.
  • Most of the PAX-5/BSAP-positive specimens were negative for Oct.2 and/or BOB.1/OBF.1 except for four CHL specimens.
  • Our results may support the WHO classification in which most cases of Hodgkin-like ALCL are classified as CHL.
  • However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. B-Cell-Specific Activator Protein / genetics. Biomarkers, Tumor / genetics. Diagnosis, Differential. Female. Gene Expression Regulation, Leukemic. Humans. Male. Middle Aged. Neoplasm Staging. Octamer Transcription Factor-2 / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Survival Analysis. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577776.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-2; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Trans-Activators; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


88. Dargent JL, Lespagnard L, Feoli F, Debusscher L, Greuse M, Bron D: De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema. Leuk Lymphoma; 2005 May;46(5):775-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema.
  • We report the case of a 79-year-old woman with a longstanding lymphedema of the right arm who developed a skin lymphoma involving the right wrist area.
  • In addition, these cells were CD5 positive.
  • No expression of anaplastic large cell lymphoma kinase (ALK), CD10, CD23, CD30, CD43, bcl-6, cyclin D1, p53 or p16INK4a could be seen.
  • This study further illustrates that lymphoma of the skin may complicate chronic limb lymphedema.
  • Like most of the previously reported cases, this neoplasm belonged to the category of diffuse large B-cell lymphoma.
  • [MeSH-major] Antigens, CD5 / biosynthesis. Lymphedema / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Arm. Chronic Disease. Female. Humans. Polymerase Chain Reaction


89. Barete S, Francés C, Charlotte F, Barrou B, Leblond V, Dereure O: Fatal outcome of deep-penetrating lower limb primary cutaneous anaplastic large cell lymphomas in two immunocompromised patients. Acta Derm Venereol; 2009 Nov;89(6):627-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal outcome of deep-penetrating lower limb primary cutaneous anaplastic large cell lymphomas in two immunocompromised patients.
  • The occurrence of primary cutaneous anaplastic large cell lymphoma (PCALCL) in immunocompromised patients is rare.
  • Only 11 cases have been reported to date, all of them in organ transplant recipients and none in patient with idiopathic CD4+ T-cell lymphocytopaenia.
  • We describe here the original clinical pattern of deep, fascia and muscle-penetrating PCALCL of the lower limb in two immunocompromised patients, one in a renal transplant recipient, the other in a patient with idiopathic CD4+ T-cell lymphocytopaenia.
  • Both patients experienced a negative outcome, contrasting with the usually indolent course of PCALCL in immunocompetent patients, since both died of complications related to the lymphoma 30 and 13 months later, respectively.
  • [MeSH-major] Immunocompromised Host. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997696.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


90. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A: The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol; 2006 Dec;34(12):1670-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
  • OBJECTIVE: Heat shock protein 90 (HSP90) chaperones and maintains the molecular integrity of a variety of signal transduction proteins, including the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) oncogenic protein, a genetic abnormality that is frequently observed in anaplastic large cell lymphoma (ALCL) cells.
  • Here we demonstrate that HSP90 is overexpressed in primary and cultured ALK-positive and ALK-negative ALCL cells, and we evaluate the potential role of the small molecule inhibitor of HSP90, 17-allylamino-17-demethoxygeldanamycin (17-AAG) in treating ALCL.
  • Apoptosis and cell-cycle arrest were determined by Annexin-V/propidium iodide and propidium iodide staining, respectively, and fluorescein-activated cell sorting analysis.
  • RESULTS: Treatment of cultured ALCL cells with 17-AAG induced cell-cycle arrest and apoptosis, irrespective of ALK expression.
  • At the molecular level, 17-AAG induced degradation of ALK and Akt proteins, dephosphorylated extracellular signal-regulated kinase, and degraded the cell-cycle regulatory protein cyclin D1 and its cyclin-dependent kinases, CDK4 and CDK6, but had a differential effect on p27 and p53 proteins.
  • Inhibition of extracellular signal-regulated kinase phosphorylation by the mitogen activated protein kinase inhibitor U0126 induced cell death in all ALCL cell lines, and sublethal concentration 17-AAG showed synergistic antiproliferative effects when combined with U0126 or doxorubicin.
  • CONCLUSION: Our data demonstrate that targeting HSP90 function by 17-AAG may offer a novel therapeutic strategy for ALCL, either as single-agent activity or by combining 17-AAG with conventional or targeted therapeutic schemes.
  • [MeSH-major] Benzoquinones / pharmacology. Butadienes / pharmacology. Doxorubicin / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Lymphoma, Large-Cell, Anaplastic / metabolism. Nitriles / pharmacology. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / drug effects. Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin D. Cyclin-Dependent Kinase 4 / drug effects. Cyclin-Dependent Kinase 4 / metabolism. Cyclin-Dependent Kinase 6 / drug effects. Cyclin-Dependent Kinase 6 / metabolism. Cyclins / drug effects. Cyclins / metabolism. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Drug Synergism. Extracellular Signal-Regulated MAP Kinases / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. G0 Phase / drug effects. G1 Phase / drug effects. Humans. Mitogen-Activated Protein Kinase 1 / drug effects. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / drug effects. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation. Receptor Protein-Tyrosine Kinases. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157164.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Butadienes; 0 / Cyclin D; 0 / Cyclins; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Nitriles; 0 / U 0126; 4GY0AVT3L4 / tanespimycin; 80168379AG / Doxorubicin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


91. Querfeld C, Kuzel TM, Guitart J, Rosen ST: Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology (Williston Park); 2007 May;21(6):689-96; discussion 699-700,
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
  • The spectrum of CD30+ lymphoproliferative diseases of the skin includes CD30+ cutaneous anaplastic large cell lymphoma, lymphomatoidpapulosis, as well as borderline cases.
  • These entities constitute the second most common group of cutaneous lymphomas according to the newly revised World Health Organization and European Organisation for Research and Treatment of Cancer consensus classification.
  • This review will provide an update on recent findings of immunologic, molecular, cytogenetic features and treatment strategies for patients with CD30+ lymphoproliferative diseases.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous. Skin Neoplasms
  • [MeSH-minor] Antigens, CD30 / metabolism. Combined Modality Therapy. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / pathology. Lymphomatoid Papulosis / therapy. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564326.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Number-of-references] 74
  •  go-up   go-down


92. Acevedo O: Determination of local effects for chloroaluminate ionic liquids on Diels-Alder reactions. J Mol Graph Model; 2009 Sep;28(2):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Diels-Alder reaction, paradigm in organic synthesis, highlights the advantages provided by ionic liquids as the reaction between cyclopentadiene and methyl acrylate in 1-ethyl-3-methylimidazolium tetrachloroaluminate and heptachlorodialuminate [EMIM][AlCl(4)] and [EMIM][Al(2)Cl(7)], respectively, has been reported to react with rates over 200 times faster and endo selectivity 10 times greater than commonly used reaction conditions.
  • Different anion-to-cation ratios were tested and a 1:1 ratio was determined to give the best agreement with experimental observations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419891.001).
  • [ISSN] 1873-4243
  • [Journal-full-title] Journal of molecular graphics & modelling
  • [ISO-abbreviation] J. Mol. Graph. Model.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ionic Liquids; 0 / Solvents
  •  go-up   go-down


93. Yang JL, Zheng SJ, He YF, Matsumoto H: Aluminium resistance requires resistance to acid stress: a case study with spinach that exudes oxalate rapidly when exposed to Al stress. J Exp Bot; 2005 Apr;56(414):1197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Al accumulated in the apical 5 mm of the roots of spinach which was also similar to that in the Al-sensitive wheat after 24 h treatment with 50 microM AlCl(3), indicating a non-exclusion mechanism.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737984.001).
  • [ISSN] 0022-0957
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Oxalates; 3CYT62D3GA / aluminum chloride
  •  go-up   go-down


94. Xu Y, McLaughlin M, Chen CY, Reamer RA, Dormer PG, Davies IW: A general method for the synthesis of 3,5-diarylcyclopentenones via friedel-crafts acylation of vinyl chlorides. J Org Chem; 2009 Jul 17;74(14):5100-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Key aspects of this approach are the intramolecular Friedel-Crafts-type cyclization of vinyl chlorides and subsequent Pd-catalyzed cross-coupling reactions.
  • The requisite vinyl chloride-bearing arylacetic acid precursors are readily available by straightforward alkylation of arylacetic acid esters and undergo cyclization to yield 3-chloro-5-aryl-2-cyclopentenones when treated with AlCl(3).

  • Hazardous Substances Data Bank. VINYL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485346.001).
  • [ISSN] 1520-6904
  • [Journal-full-title] The Journal of organic chemistry
  • [ISO-abbreviation] J. Org. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pentanones; R0053Y1AZ7 / 1-pentene-3-one; WD06X94M2D / Vinyl Chloride
  •  go-up   go-down


95. Zhang J, Xie S, Ho YS: Removal of fluoride ions from aqueous solution using modified attapulgite as adsorbent. J Hazard Mater; 2009 Jun 15;165(1-3):218-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modified attapulgite with a mass ratio attapulgite:Mg Cl(2)x6H(2)O:AlCl(3)x2H(2)O=2:1:2 had higher fluoride adsorption capacity.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. MAGNESIUM COMPOUNDS .
  • Hazardous Substances Data Bank. ATTAPULGITE .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. MAGNESIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013016.001).
  • [ISSN] 1873-3336
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Magnesium Compounds; 0 / Silicon Compounds; 02F3473H9O / Magnesium Chloride; 3CYT62D3GA / aluminum chloride; Q80VPU408O / Fluorides; U6V729APAM / attapulgite
  •  go-up   go-down


96. Eiden P, Liu Q, Zein El Abedin S, Endres F, Krossing I: An experimental and theoretical study of the aluminium species present in mixtures of AlCl3 with the ionic liquids [BMP]Tf2N and [EMIm]Tf2N. Chemistry; 2009;15(14):3426-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is known that nano- or microcrystalline aluminium may be electrodeposited from mixtures of AlCl(3) and the ionic liquids 1-butyl-1-methylpyrrolidinium bis(trifluoromethylsulfonyl)amide ([BMP]Tf(2)N) and 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)amide ([EMIm]Tf(2)N), and that two phases form with higher formal concentrations of AlCl(3) (at 1.6 mol L(-1) (x(Al)=0.33) and 2.5 mol L(-1) (x(Al)=0.39), respectively).
  • The addition of AlCl(3) to the two liquids first leads to complexation with [Tf(2)N](-) and then disproportionation of the initial [AlCl(x)(Tf(2)N)(y)](-) complexes give Al(Tf(2)N)(3) and [AlCl(4)](-).
  • At high concentrations of AlCl(3), the lower phase consists almost completely of Al(Tf(2)N)(3), whereas in the upper phase [AlCl(4)](-) is the dominant species.
  • Electrodeposition of aluminium in the upper phase occurs from mixed AlCl(x)(Tf(2)N)(y) species, most likely from [AlCl(2)(Tf(2)N)(2)](-) formed in small concentrations at the phase boundary between the [AlCl(4)](-) and the Al(Tf(2)N)(3) layers.
  • Moreover, the ionic liquids [BMP]AlCl(4) (m.p.
  • 74 degrees C) and [EMIm]AlCl(4) (m.p.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229940.001).
  • [ISSN] 1521-3765
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Guo CH, Lu YF, Hsu GS: The influence of aluminum exposure on male reproduction and offspring in mice. Environ Toxicol Pharmacol; 2005 Jul;20(1):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Al chloride, AlCl(3), was administered subcutaneously to CD-1 adult male mice at dosages of 0, 7, or 13mg Al/kg body weight/day for 2 weeks of pre-mating periods.
  • The mean mating frequencies of the Al-treated groups reduced consistently from week 4 to 6, and a dramatic reduction in male fertility was also observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21783580.001).
  • [ISSN] 1382-6689
  • [Journal-full-title] Environmental toxicology and pharmacology
  • [ISO-abbreviation] Environ. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Birgersdotter A, Baumforth KR, Wei W, Murray PG, Sjöberg J, Björkholm M, Porwit A, Ernberg I: Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. Am J Clin Pathol; 2010 Feb;133(2):271-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas.
  • Microarray analysis of 44 classical Hodgkin lymphoma (cHL) samples showed higher CTGF messenger RNA expression in the nodular sclerosis (NS) than in the mixed cellularity (MC) subtype.
  • When analyzed by immunohistochemical analysis, Hodgkin-Reed-Sternberg (H-RS) cells and macrophages in 23 cHLs and "popcorn" cells in 2 nodular lymphocyte predominant Hodgkin lymphomas showed expression of CTGF protein correlating with the extent of fibrosis.
  • Malignant cells in 32 samples of various non-Hodgkin lymphomas were negative for CTGF.
  • A staining pattern of stromal cells similar to that of NS cHL was seen in anaplastic large cell lymphoma.
  • Macrophages stained positively in Burkitt lymphomas and in some mantle cell lymphomas.
  • [MeSH-major] Connective Tissue Growth Factor / metabolism. Hodgkin Disease / metabolism. Lymphoma, B-Cell / metabolism


99. Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J: SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood; 2006 May 15;107(10):4130-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic large-cell lymphoma (ALCL) is frequently associated with the 2;5 translocation and expresses the NPM-ALK fusion protein, which possesses a constitutive tyrosine kinase activity.
  • We analyzed SHP1 tyrosine phosphatase expression and activity in 3 ALK-positive ALCL cell lines (Karpas 299, Cost, and SU-DHL1) and in lymph node biopsies (n = 40).
  • Furthermore, confocal microscopy performed on ALCL cell lines and biopsy specimens showed the colocalization of the 2 proteins in cytoplasmic bodies containing Y664-phosphorylated NPM-ALK.
  • Downregulation of SHP1 expression by RNAi in Karpas cells led to hyperphosphorylation of NPM-ALK, STAT3 activation, and increase in cell proliferation.
  • Furthermore, SHP1 overexpression in 3T3 fibroblasts stably expressing NPM-ALK led to the decrease of NPM-ALK phosphorylation, lower cell proliferation, and tumor progression in nude mice.
  • The use of tissue microarrays revealed that 50% of ALK-positive ALCLs were positive for SHP1.
  • Our results suggest that SHP1 could be a critical enzyme in ALCL biology and a potential therapeutic target.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Protein Tyrosine Phosphatases / metabolism. Protein-Tyrosine Kinases / physiology
  • [MeSH-minor] Base Sequence. Cell Line. Cytoplasm / physiology. DNA Primers. Humans. Microscopy, Confocal. Phosphoric Monoester Hydrolases / metabolism. Phosphorylation. Protein Tyrosine Phosphatase, Non-Receptor Type 6. RNA, Small Interfering / genetics. Recombinant Fusion Proteins / metabolism. Signal Transduction / physiology

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469875.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering; 0 / Recombinant Fusion Proteins; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTPN6 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


100. Mussolin L, Pillon M, Bonato P, Leszl A, Franceschetto G, Di Meglio A, d'Amore ES, Sainati L, Rosolen A: Cytogenetic analysis of pediatric anaplastic large cell lymphoma. Pediatr Blood Cancer; 2010 Sep;55(3):446-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of pediatric anaplastic large cell lymphoma.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) constitutes approximately 15% of pediatric and 3% of adult non-Hodgkin lymphomas.
  • Cytogenetic studies of ALCL have mostly been published as case-reports.
  • The aim of this study was to determine the cytogenetic profiles of a series of pediatric ALCL and to compare them with pediatric and adult ALCL from the literature.
  • Comparative analysis was performed on our findings and on the karyotypes of 48 pediatric and 39 adult ALCL reported in the literature.
  • RESULTS: Karyotype was obtained in 16/18 ALCL: 9 showed translocation t(2;5) and 1 an alk variant form.
  • Trisomy 7 was found in 22% (13/59) of pediatric cases with abnormal karyotype and only in 5% (2/38) of adults; monosomy of chromosome 13 in 13% (5/38) of adults and only in 2% (1/59) of pediatric patients and monosomy of chromosome 15 in 16% (6/38) of adults and in none of the pediatric ALCL.
  • CONCLUSION: Our data suggest that pediatric and adult ALCL are characterized by different numerical chromosomal abnormalities.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658615.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down






Advertisement